Revised. Amendments from Version 1
==================================

Previously, we presented phased biallelic SNVs called *de novo*using sequence data from the 1000 Genomes Project aligned to GRCh38. This work included calls for 2,548 samples spanning 26 populations. Here, we extend that work to add biallelic INDELs, which are combined with the biallelic SNV calls into a single phased call set. Further, we extend the benchmarking work presented in the previous version of the data note to the combined SNV and INDEL call set. We also add comparisons with the 1000 Genomes Project calls lifted over to GRCh38 and look in further detail at clinically important loci where the reference genome changed between GRCh37 and GRCh38. Figures have been added in these instances. Additional information has been added, such as the contribution of the multiple callers used in this work to the integrated call set. The text has been revised throughout, reflecting the updates to the data set, additional analyses and efforts to improve the manuscript in line with the comments from our reviewers. As we have extensively rewritten the manuscript, we would encourage readers to treat this as they would a new document. We also note that the SNV-only data set previously described remains available and that a revised description of its production, based on reviewer comments, is included in this version.

Introduction
============

The 1000 Genomes Project produced a deep catalogue of human genomic variation and sequenced more than 2600 samples from 26 different populations. It completed its final phase ("phase three"), with the release of more than 85 million variants of various types and phased haplotypes for those variants ^[@ref-1]^. This data has been widely used by the scientific community for genotype imputation and many other applications ^[@ref-2]^. The strategy adopted by the project consisted of sequencing samples using low coverage whole genome sequencing (WGS) and whole exome sequencing (WES), and the alignment of that sequence data to a version of the GRCh37 human reference genome, which included decoy sequences for optimal read mapping.

While the 1000 Genomes Project was based on GRCh37, the current version of the human reference assembly is GRCh38, which was released by the Genome Reference Consortium (GRC) in 2013. This is the most comprehensive representation of the human genome currently available, as demonstrated by Schneider *et al.*, whose work illustrates the superiority of GRCh38 over GRCh37 ^[@ref-3]^. Specifically GRCh38 is a better basis for annotation, alters read alignment (even in unchanged regions of the genome) and "impacts variant interpretation at clinically relevant loci" ^[@ref-3]^.

To make full use of GRCh38, there has been a need for widely used genomic reference data sets, like the 1000 Genomes Project data, to be made available on the assembly so that pipelines and analyses that rely on such additional reference materials can use GRCh38 and benefit from its improvements.

[dbSNP](https://www.ncbi.nlm.nih.gov/snp) have facilitated the use of the 1000 Genomes Project variation data on GRCh38 by transferring the variant calls to the new assembly using a method relying on an alignment created between GRCh37 and GRCh38. The alignment is then used to determine equivalent locations between the two assemblies, allowing variation data to be "lifted-over". Files from dbSNP are reformatted into a standard VCF by the [European Variation Archive](https://www.ebi.ac.uk/eva/) (EVA) and shared as part of our resources through the [1000 Genomes FTP site](ftp://ftp.1000genomes.ebi.ac.uk/vol1/ftp/release/20130502/supporting/GRCh38_positions) ^[@ref-4]^ and also via the Ensembl genome browser ^[@ref-5]^.

Lift-over approaches, however, have several limitations. First, in order to be able to transfer a variant from one assembly to another, it is necessary to be able to map between the genomes at the variant's original location, which is not always possible. In the lift-over process mentioned above there were over 2.3 million VCF records which could not be transferred to the GRCh38 assembly. Second, even when a variant can be lifted-over it does not follow that the underlying read alignments supporting the variant identification on the original assembly would transfer to the identified location in the new assembly. Indeed, alterations to the genome have an impact on read alignments even in unaltered regions of the genome ^[@ref-3]^. Thus, despite a variant being lifted-over, there is no guarantee that it would have been called at the identified location in the new genome as the underlying evidence may vary. Finally, where novel sequence is introduced in GRCh38, it is unlikely that the lift-over approach will be effective as this sequence was not represented in the older assembly and, therefore, not included in the original variation discovery process. Examples of this can be seen where gaps in the assembly have been closed, including at medically relevant loci where gaps have been closed, such as *INPP5D*, *DPP6* and *IKZF1* ^[@ref-3]^, and which are considered below.

To realise the benefits and address the limitations described above, we created new call sets from alignments of the original 1000 Genomes Project read data to GRCh38, initially releasing only biallelic SNVs (described in a previous version of this note) and now updating to biallelic SNVs and INDELs. While this work does not replicate the full repertoire of analyses employed by the 1000 Genomes Consortium, it aims to give a consistent *de novo* call set spanning all of the GRCh38 primary assembly autosomes and pseudo-autosomal regions, and to produce a call set with similar, although not identical, properties to that produced by the 1000 Genomes Project while using a simpler methodology.

To create an updated variation call set from the 1000 Genomes Project data, we adopted a multi-caller approach and used previously described alignments ^[@ref-6]^. With the aim of sharing this data in a timely manner, we adopted an incremental approach to generating and releasing data sets. Initially, we released only biallelic SNVs, which represent the vast majority of the SNVs present in the human genome. Phase three of the 1000 Genomes Project reported that 99.6% of the 81.4 million SNVs they reported are biallelic. Here, we extend our biallelic SNV call set by adding biallelic INDELs. We anticipate future updates to incorporate calls on new populations and the non-pseudo autosomal regions of chromosome X.

Methods
=======

Input data
----------

The methods used for sample collection, library construction, and sequencing are described in the previous 1000 Genomes Project publications ^[@ref-1],\ [@ref-7],\ [@ref-8]^. The read data used for this analysis used similar criteria to the final phase of the 1000 Genomes Project. Only Illumina sequence data with reads longer than 70 bp (WGS) and 68 bp (WES) were used. This data was aligned to GRCh38 as previously described ^[@ref-6]^. The complete list of the whole genome and whole exome sequencing alignment files used as the input for generating the callsets can be found on our FTP site at [ftp://ftp.1000genomes.ebi.ac.uk/vol1/ftp/data_collections/1000_genomes_project/1000genomes.low_coverage.GRCh38DH.alignment.index](ftp://ftp.1000genomes.ebi.ac.uk/vol1/ftp/data_collections/1000_genomes_project/1000genomes.exome.GRCh38DH.alignment.index) and at <ftp://ftp.1000genomes.ebi.ac.uk/vol1/ftp/data_collections/1000_genomes_project/1000genomes.exome.GRCh38DH.alignment.index>.

Reference genome
----------------

We used the full GRCh38 reference, including ALT contigs, decoy and EBV sequences (accession [GCA_000001405](https://www.ncbi.nlm.nih.gov/assembly/GCF_000001405)). In addition, more than 500 HLA sequences compiled by Heng Li from the IMGT/HLA database provided by the Immuno Polymorphism Database (IPD) ^[@ref-9]^ are included. The reference genome can be accessed at <ftp://ftp.1000genomes.ebi.ac.uk/vol1/ftp/technical/reference/GRCh38_reference_genome/>.

Ethical considerations
----------------------

Information concerning ethical approval and the informed consent procedure for the 1000 Genomes Project can be found at [https://www.internationalgenome.org/sites/1000genomes.org/files/docs/Informed%20Consent%20Background%20Document.pdf](https://www.internationalgenome.org/sites/1000genomes.org/files/docs/InformedConsentBackgroundDocument.pdf).

Quality control of the alignment files
--------------------------------------

We adopted a similar quality control process to that used in the final phase of the 1000 Genomes Project. The following describes the methods used in their entirety. [Chk_indel_rg](https://github.com/lh3/samtools-legacy/blob/master/examples/chk_indel.c) was applied to discard alignment files with an unbalanced ratio of short insertions and deletions (greater than 5). [Picard CollectWgsMetrics](https://broadinstitute.github.io/picard/command-line-overview.html#CollectWgsMetrics) was used with the whole genome files and those with mean non-duplicated aligned coverage level ≤2x were discarded. In the case of the exome files, we used [Picard CollectHsMetrics](https://broadinstitute.github.io/picard/command-line-overview.html#CollectHsMetrics) using the exome target coordinates at [ftp.1000genomes.ebi.ac.uk/vol1/ftp/data_collections/1000_genomes_project/working/20190125_coords_exon_target/](http://ftp.1000genomes.ebi.ac.uk/vol1/ftp/data_collections/1000_genomes_project/working/20190125_coords_exon_target/) and keeping files where more than 70% of the target regions have 20× or greater coverage. In addition, VerifyBAMID ^[@ref-10]^ was used to assess sample contamination and mix-ups and the following cutoffs were used:

-   free_mix \> 0.03 and chip_mix \> 0.02 for whole genome files

-   free_mix \> 0.035 and chip_mix \> 0.02 for exome files

Only files passing the quality assessment were used in variant calling.

Variant discovery
-----------------

Callers were selected in consultation with members of the original 1000 Genomes Project, using their prior knowledge of caller output and the feasibility of running callers on the data set. This enabled us to take advantage of knowledge of a wide range of callers and their performance with this data, the profile of which is now atypical. Specifically, these data are low-coverage from samples representing a diverse range of populations, which necessitates a strategy relying on joint genotyping and the presence of many individuals from a given population. Four supporting call sets were created, using different callers and combinations of the exome and WGS sequence data.

A total of 2,659 WGS and 2,498 WES BAMs corresponding to 2,698 samples ^[@ref-6]^ were used for variant identification. [Figure 1](#f1){ref-type="fig"} details the analysis of the alignment files with three established methods ( [BCFtools](http://samtools.github.io/bcftools/) version 1.3.1-220-g9f38991, [Freebayes](https://github.com/ekg/freebayes) version v1.0.2-58-g054b257 and [GATK](https://software.broadinstitute.org/gatk/) UnifiedGenotyper ^[@ref-11]^ version 3.5-0-g36282e4). BCFtools was used to analyse WGS and WES files in two independent runs, GATK UnifiedGenotyper was used only with WGS files and Freebayes was used to analyse everything together (WGS+WES). Calls were made only on the primary assembly autosomes and pseudo-autosomal regions. The following command lines were used for each of the methods to perform joint genotyping:     • BCFtools with the WGS files:bcftools mpileup -E -a DP -a SP -a AD -P ILLUMINA \\ -pm3 -F0.2 -C50 -d 700000 \\ -f \$ref.fa \$file.bam \| bcftools call -mv -O z \\ \--ploidy GRCh38 -S \$samples.ped -o \$out.vcf.gz    • GATK UnifiedGenotyper with the WGS files:java -Xmx6g -jar GenomeAnalysisTK.jar \\ -T UnifiedGenotyper \\ -R \$ref.fa \\ -I \$file.bam \\ -o \$out.vcf.gz \\ -dcov 250 \\ -stand_emit_conf 10 \\ -glm both \\ \--genotyping_mode GENOTYPE_GIVEN_ALLELES \\ \--dbsnp ALL_20141222.dbSNP142_human_GRCh38.snps.vcf.gz \\ -stand_call_conf 10    • BCFtools with the WES files:bcftools mpileup -E -a DP -a SP -a AD -P ILLUMINA \\ -pm3 -F0.2 -C50 -d 1400000 \\ -f \$ref.fa \$file.bam \| bcftools call -mv -O z \\ \--ploidy GRCh38 -S \$samples.ped -o \$out.vcf.gz    • Freebayes with the WGS+WES files:freebayes \--genotyping-max-iterations 10 \\ \--min-alternate-count 3 \\ \--max-coverage 2000000 \\ \--min-mapping-quality 1 \\ \--min-alternate-qsum 50 \\ \--min-base-quality 3 \\ -f \$ref.fa \\ -b \$file.bam \| bgzip -c \> \$out.vcf.gz

![Schematic representation of our approach illustrating the entire process from the alignment files previously generated to the generation of the four supporting callsets and finally to the production of the final phased consensus callset.\
VCF, variant call format; WGS, whole-genome sequencing; WES, whole-exome sequencing; VQSR, variant quality score recalibration.](wellcomeopenres-4-17129-g0000){#f1}

Variant filtering
-----------------

Our variant discovery pipeline produced four initial call sets as described above. To create an integrated call set, we discarded the variants falling in the centromeres, as these are regions of low complexity that hinder variant calling. Variants on the Y chromosome or in regions of the X chromosome outside the pseudo-autosomal regions were discarded due to the ploidy settings used in this work. Additionally, the initial call sets were filtered using different methods and parameters depending on the call set:

***GATK UnifiedGenotyper call set***. We used the VariantScoreRecalibration (VQSR) ^[@ref-11]^ method following the GATK best practices and GATK training call sets. The combination of commands and parameters we used were different depending on the variant type being analysed. For SNPs we used GATK VariantRecalibrator and ApplyRecalibration as follows:

java -jar GenomeAnalysisTK.jar \\ -T VariantRecalibrator \\ -R \$ref.fa \\ -input \$file.vcf.gz \\ -resource:hapmap,known=false,training=true,truth=true,prior=15.0 hapmap_3.3.hg38.vcf.gz \\ -resource:omni,known=false,training=true,truth=true,prior=12.0 1000G_omni2.5.hg38.vcf.gz \\ -resource:1000G,known=false,training=true,truth=false,prior=10.0 1000G_phase1.snps.high_confidence.hg38.vcf.gz \\ -resource:dbsnp,known=true,training=false,truth=false,prior=2.0 dbsnp_146.hg38.vcf.gz \\ -an DP \\ -an QD \\ -an FS \\ -an SOR \\ -an MQ \\ -an MQRankSum \\ -an ReadPosRankSum \\ -an InbreedingCoeff \\ -mode SNP \\ -tranche 100.0 -tranche 99.9 -tranche 99.0 -tranche 98.0 -tranche 97.0 -tranche 96.0 -tranche 95.0 -tranche 92.0 -tranche 90.0 -tranche 85.0 -tranche 80.0 -tranche 75.0 -tranche 70.0 -tranche 65.0 -tranche 60.0 -tranche 55.0 -tranche 50.0 \\ -recalFile recalibrate_SNP.recal \\ -tranchesFile recalibrate_SNP.tranches \\ -rscriptFile recalibrate_SNP_plots.R

And:

java -jar GenomeAnalysisTK.jar -T ApplyRecalibration \\ -R \$ref.fa \\ -input \$file.vcf.gz \\ -mode SNP \\ \--ts_filter_level 99.9 \\ -recalFile recalibrate_SNP.recal \\ -tranchesFile recalibrate_SNP.tranches \| bgzip -c \> recalibrated_snps_raw_indels.vcf.gz

And for INDELs we used:

java -jar GenomeAnalysisTK.jar \\ -T VariantRecalibrator \\ -R \$ref.fa \\ -input recalibrated_snps_raw_indels.vcf.gz \\ -resource:mills,known=false,training=true,truth=true,prior=12.0 Mills_and_1000G_gold_standard.indels.hg38.vcf.gz \\ -resource:dbsnp,known=true,training=false,truth=false,prior=2.0 dbsnp_146.hg38.vcf.gz \\ -an QD \\ -an DP \\ -an FS \\ -an SOR \\ -an ReadPosRankSum \\ -an MQRankSum \\ -an InbreedingCoeff \\ -mode INDEL \\ -tranche 100.0 -tranche 99.9 -tranche 99.0 -tranche 98.0 -tranche 97.0 -tranche 96.0 -tranche 95.0 -tranche 92.0 -tranche 90.0 -tranche 85.0 -tranche 80.0 -tranche 75.0 -tranche 70.0 -tranche 65.0 -tranche 60.0 -tranche 55.0 -tranche 50.0 \\ -recalFile recalibrate_INDEL.recal \\ -tranchesFile recalibrate_INDEL.tranches \\ -rscriptFile recalibrate_INDEL_plots.R \\ \--maxGaussians 4

And:

java -jar GenomeAnalysisTK.jar \\ -T ApplyRecalibration \\ -R \$ref.fa \\ -input recalibrated_snps_raw_indels.vcf \\ -mode INDEL \\ \--ts_filter_level 80.0 \\ -recalFile recalibrate_INDEL.recal \\ -tranchesFile recalibrate_INDEL.tranches \| bgzip -c \> recalibrated_variants.vcf.gz

***BCFTools call sets***. Filtering was based on variant annotations. The variant annotations used in the filtering and their respective cutoff values were established by comparing the distribution of the annotation values in the true and false positive sites. In the case of the low coverage data we compared the sites in chromosome 20 only and in the case of the exome data we used sites on all chromosomes. We considered true positives to be the sites identified in our call set for genome NA12878 that were also present in the gold-standard call set generated for the same sample by [Genome in a Bottle](https://github.com/genome-in-a-bottle) (GIAB). GIAB's calls for NA12878 are the result of an effort to integrate data generated by 13 different sequencing technologies and analysis methods ^[@ref-12]^. Sites that were present in our call sets and absent in GIAB were considered false positive sites. [Table 1](#T1){ref-type="table"} and [Table 2](#T2){ref-type="table"} show the variant annotations and cutoff values used for the SNPs and INDELs with the low coverage data and [Table 3](#T3){ref-type="table"} and [Table 4](#T4){ref-type="table"} show the annotations and cutoff values used for the exome data with the SNPs and INDELs respectively.

###### Variant annotations and cutoff values used for SNPs identified using the low coverage data.

  Annotation   Description                                             Cutoff value
  ------------ ------------------------------------------------------- --------------
  INFO/DP      Raw read depth                                          \>24,304
  INFO/MQ      Average mapping quality                                 \<34
  INFO/MQ0F    Fraction of MQ0 reads (smaller is better)               \>0.049737
  INFO/HOB     Bias in the number of HOMs number (smaller is better)   \>0.1643732
  INFO/SGB     Segregation based metric                                \>2347.043
  INFO/SGB     Segregation based metric                                \<-64440.286
  QUAL         Variant quality                                         \<20

###### Variant annotations and cutoff values used for INDELs identified using the low coverage data.

  Annotation   Description                                             Cutoff value
  ------------ ------------------------------------------------------- ---------------
  INFO/DP      Raw read depth                                          \>23,758
  INFO/MQ      Average mapping quality                                 \<41
  INFO/MQ0F    Fraction of MQ0 reads (smaller is better)               \>0.009913696
  INFO/HOB     Bias in the number of HOMs number (smaller is better)   \>0.20265508
  INFO/SGB     Segregation based metric                                \>2143.8876
  INFO/SGB     Segregation based metric                                \<-29513.557
  INFO/IDV     Maximum number of reads supporting an indel             \>51
  INFO/IMF     Maximum fraction of reads supporting an indel           \<0.387097
  QUAL         Variant quality                                         \<20

###### Variant annotations and cutoff values used for SNPs identified using the exome data.

  Annotation   Description                                             Cutoff value
  ------------ ------------------------------------------------------- --------------
  INFO/DP      Raw read depth                                          \>656,519
  INFO/MQ      Average mapping quality                                 \<38
  INFO/MQ0F    Fraction of MQ0 reads (smaller is better)               \>0.0146629
  INFO/HOB     Bias in the number of HOMs number (smaller is better)   \>0.1536016
  INFO/SGB     Segregation based metric                                \>57489.21
  INFO/SGB     Segregation based metric                                \<-226326.93
  QUAL         Variant quality                                         \<20

###### Variant annotations and cutoff values used for INDELs identified using the exome data.

  Annotation   Description                                             Cutoff value
  ------------ ------------------------------------------------------- ---------------
  INFO/MQ      Average mapping quality                                 \<45
  INFO/MQ0F    Fraction of MQ0 reads (smaller is better)               \>0.002034686
  INFO/HOB     Bias in the number of HOMs number (smaller is better)   \>0.269603
  INFO/SGB     Segregation based metric                                \>53165.5
  INFO/SGB     Segregation based metric                                \<-85919.729
  INFO/IMF     Maximum fraction of reads supporting an indel           \<0.3323922
  QUAL         Variant quality                                         \<20

These cutoff values were applied using the following command:

     • SNPs from the low coverage data:

bcftools filter -s GIABFILTER \\ -e\'INFO/DP\>24304 \| MQ\<34 \| MQ0F\>0.049737 \| HOB\>0.1643732 \| SGB\>2347.043 \| SGB\<-64440.286 \| QUAL\<20\' \\ \$file.snps.vcf.gz \\ -o \$out.snps.filtered.vcf.gz -O z

     • INDELs from the low coverage data:

bcftools filter -s GIABFILTER \\ -e\'INFO/DP\>23758 \| MQ\<41 \| MQ0F\>0.009913696 \| HOB\>0.20265508 \| SGB\>2143.8876 \| SGB\<-29513.557 \| IDV\>51 \| IMF\<0.387097 \| QUAL\<20\' \$file.indels.vcf.gz -o \$out.indels.filtered.vcf.gz -O z

     • SNPs from the exome data:

bcftools filter -sGIABFILTER \\ -e\'INFO/DP\>656519 \| MQ\<38 \| MQ0F\> 0.0146629\| HOB\>0.1536016 \| SGB\>57489.21 \| SGB \< -226326.93\| QUAL\<20\' \$file.snps.vcf.gz \\ -o \$out.snps.filtered.vcf.gz -O z

     • INDELs from the exome data:

bcftools filter -sGIABFILTER \\ -e\'MQ\<45 \| MQ0F\>0.002034686\| HOB\> 0.269603\| SGB\>53165.5 \| SGB\<-85919.729 \| IMF\<0.3323922 \| QUAL\<20\' \$file.indels.vcf.gz \\ -o \$out.indels.filtered.vcf.gz -O z

***Freebayes call set***. We used a simple hard filter that discarded variants having a QUAL value less than or equal to 1 since this cutoff value has been recommended by the author of Freebayes (personal communication, \[Erik Garrison\]) and proved to be effective in filtering variants in phase three of the 1000 Genomes Project. This filter was applied using the following command:

bcftools filter -sQUALFILTER -e\'QUAL\<1\' \$file.vcf.gz \\ -o \$file.filtered.vcf.gz -O z

Generating consensus call sets
------------------------------

***Biallelic SNVs***. First, each call set was normalized using the following combination of tools:

bcftools norm -f ref.fa -o norm.vcf.gz -m \'-both' in.vcf.gz -Oz

in order to normalize and left-align INDELs and to split the multiallelic sites into multiple rows. Then we run:

vcfallelicprimitives norm.vcf.gz \--keep-info \--keep-geno \| vt sort - \| vt uniq - \| bgzip -c \> norm.aprimitives.vcf.gz

where [vcflib](https://github.com/vcflib/vcflib) vcfallelicprimitives (version v1.0.0-rc1) was used to decompose the complex variants and [vt](https://github.com/atks/vt) ^[@ref-13]^ (version 0.5) was used to sort and unify resulting variants. After this we run:

bcftools norm -f ref.fa -o norm.aprimitives.merged.vcf.gz -m \'+both' norm.aprimitives.vcf.gz -Oz

this merges the multiallelic sites into single rows. Finally, the multiallelic sites were discarded in the following step:

bcftools view -o norm.aprimitives.merged.biallelic.vcf.gz -O z -m2 -M2 norm.aprimitives.merged.vcf.gz

This normalization procedure is necessary as different variant callers may describe the same variant in different ways, which makes comparison difficult and affects the integration of the call sets. Additionally, GATK VariantsToAllelicPrimitives was used to decompose the multi-nucleotide polymorphisms (MNPs) that were present in the Freebayes call set.

Finally, we generated a consensus call set by taking the union of the biallelic sites from each call set and calculating the genotype likelihoods for each site using GATK UnifiedGenotyper in 'genotype_given_alleles' (GGA) mode using the following command line:

java -jar GenomeAnalysisTK.jar \\ -T UnifiedGenotyper \\ -R \$ref.fa \\ -I input.\$chr:\$start-\$end.bam \\ -glm SNP \\ \--intervals \$chr:\$start-\$end \\ \--intervals integrated.biallelic.sites.vcf.gz \\ \--output_mode EMIT_ALL_SITES \\ \--alleles integrated.biallelic.sites.vcf.gz \\ \--interval_set_rule INTERSECTION \\ \--genotyping_mode GENOTYPE_GIVEN_ALLELES \\ \--max_deletion_fraction 1.5

Where `$chr:$start-$end` is the genomic chunk that is being analysed and `integrated.biallelic.sites.vcf.gz` is the VCF containing the union of the biallelic sites for which the genotype likelihoods will be calculated.

We then filtered the variants using Variant Quality Score Recalibration (VQSR) with the same parameters and training call sets that were described above and used for filtering the supporting call set generated using GATK UnifiedGenotyper. GATK ApplyRecalibrator was used with a `--ts_filter_level` value of 99.5, chosen to balance sensitivity and specificity. This gave a consensus biallelic SNV call set, used as the basis of the initial biallelic SNV-only call set.

***Biallelic SNVs and INDELs***. To add the INDEL variants to the SNV-only data set (for our second data release), we extracted the INDELs from the initial BCFTools, GATK and Freebayes call sets described above and generated a consensus call set by taking the union of the normalized biallelic INDELs from each call set. Then, we calculated the genotype likelihoods for each site using again GATK UnifiedGenotyper in 'genotype_given_alleles' (GGA) mode using the following command line:

java -jar GenomeAnalysisTK.jar \\ -T UnifiedGenotyper \\ -R \$ref.fa \\ -I input.\$chr:\$start-\$end.bam \\ -glm INDEL \\ \--intervals \$chr:\$start-\$end \\ \--intervals integrated.biallelic.indel.sites.vcf.gz \\ \--output_mode EMIT_ALL_SITES \\ \--alleles integrated.biallelic.indel.sites.vcf.gz \\ \--interval_set_rule INTERSECTION \\ \--genotyping_mode GENOTYPE_GIVEN_ALLELES \\ \--max_deletion_fraction 1.5

Where `$chr:$start-$end` is the genomic chunk that is being analysed and `integrated.biallelic.indel.sites.vcf.gz` is the VCF containing the union of the biallelic INDEL sites for which the genotype likelihoods will be calculated.

The next step consisted of filtering this INDEL-only consensus call set, and as we did for the SNV-only call set, we used the GATK Variant Quality Score Recalibration (VQSR) method, this time running ApplyRecalibrator with a `--ts_filter_level` value of 99.0. This is lower than the value of 99.5 used with the SNV-only data set. This was chosen to focus on specificity, due to the greater challenges in INDEL calling, while also balancing sensitivity.

Finally, the INDEL-only consensus call set was merged to the initial SNV-only call set by using bcftools concat.

Phasing and imputation of the consensus call set
------------------------------------------------

***Biallelic SNVs***. The VCF file containing the genotype likelihoods obtained following the procedure described above was divided into single chromosome VCF files that were further divided into genomic chunks containing 2,100 sites of which 600 were shared between consecutive chunks. These chunks were processed in parallel by [Beagle](https://faculty.washington.edu/browning/beagle/beagle.html) ^[@ref-14]^ by using the following command:

java -jar beagle.08Jun17.d8b.jar \\ chrom=\$chr:\$start-\$end \\ gl=\$chr.biallelic.GL.vcf.gz \\ out=\$chr.\$start.\$end.beagle \\ niterations=15

Where `$chr.biallelic.GL.vcf.gz` is the VCF file containing the genotype likelihoods.

After processing all the chunks with Beagle, the initial set of genotypes and haplotypes were phased using [SHAPEIT2](https://mathgen.stats.ox.ac.uk/genetics_software/shapeit/shapeit.html) ^[@ref-15]^ (version v2.r837) onto a highly accurate haplotype scaffold also created by SHAPEIT2 using microarray genotype data available on the same samples. This scaffold was obtained by leveraging family information and running SHAPEIT2 in two different independent runs on either the Illumina Omni 2.5 or Affymetrix 6.0 microarray data that was generated as part of the 1000 Genomes Project. To create the microarray scaffolds SHAPEIT2 was run using the following settings (\--window 0.5, \--states 200, \--burn 10, \--prune 10, \--main 50, \--duohmm) and SNPs with a missing data rate above 10% and a Mendel error rate above 5% were removed before phasing. Genotypes called by Beagle with a posterior probability greater than 0.995 were fixed as known genotypes and haplotypes estimated by Beagle were used to initialize the SHAPEIT2 phasing. This phasing was run in chunks of 12,250 sites with 3,500 sites overlapping between consecutive chunks. When phasing the calls derived from sequence data onto the microarray scaffolds SHAPEIT2 was run using the following command:

shapeit -call \\ \--input-gen input.shapeit.\$chr.gen.gz input.shapeit.\$chr.gen.sample \\ \--input-init input.shapeit.\$chr.hap.gz input.shapeit.hap.sample \\ \--input-scaffold chip.omni.snps.\$chr.haps chip.omni.snps.\$chr.sample chip.affy.snps.\$chr.haps chip.affy.snps.\$chr.sample \\ \--input-map \$chr.gmap.gz \\ \--input-thr 1 \\ \--window 0.1 \\ \--states 400 \\ \--states-random 200 \\ \--burn 0 \\ \--run 12 \\ \--prune 4 \\ \--main 20 \\ \--input-from \$chunk_start \\ \--input-to \$chunk_end \\ \--output-max out.\$chr.\$chunk_start.\$chunk_end.haps.gz out.\$chr.\$chunk_start.\$chunk_end.haps.sample

Where \--input-gen specifies the genotype/GL input data from Beagle, \--input-init specifies the haplotypes from Beagle, \--input-map specifies the genetic map used in the estimation, \--input-scaffold gives the SNP-array derived haplotype scaffold obtained from SHAPEIT2. The genetic map used was downloaded from <https://data.broadinstitute.org/alkesgroup/Eagle/downloads/tables/genetic_map_hg38_withX.txt.gz>. Each of the phased chunks resulting from running SHAPEIT2 were joined together using the program [ligateHAPLOTYPES](https://mathgen.stats.ox.ac.uk/genetics_software/shapeit/files/ligateHAPLOTYPES.tgz).

The strategy described here was used in the final phase of the 1000 Genomes Project and has been shown to produce low error rates for genotype calls ^[@ref-16]^.

The pipelines used in this work were implemented using the eHive workflow system ^[@ref-17]^ and modules developed in Perl and Python, which have been packaged for ease of deployment. All the analyses were run in parallel on a high-throughput compute cluster to ensure completion in a reasonable timeframe. Code is publicly available via GitHub (see software availability section) ^[@ref-17]--\ [@ref-19]^.

***Biallelic SNVs and INDELs***. The merged VCF for biallelic SNVs and INDELs was phased and imputed using Beagle/SHAPEIT2, using the same process described above for phasing and imputation of the SNV-only data set.

To illustrate the contribution of each of the four filtered supporting call sets to the final consensus call set, we generated the plots in [Figure 2](#f2){ref-type="fig"} and [Figure 3](#f3){ref-type="fig"}, for SNVs and INDELs respectively. [Figure 2](#f2){ref-type="fig"} shows that the call set that has contributed the most to the final SNV consensus call set is the GATK UnifiedGenotyper call set (71,353,714 variants) followed by the Freebayes call set (61,625,466 variants). In the case of INDELs the call set that has contributed the most to the final INDEL consensus call set is the Freebayes call set (3,649,204 variants) followed by the BCFTools call set used on the low-coverage WGS data (3,602,996 variants).

![UpSet plot analysing the contribution of each of the four supporting call sets to the final SNV consensus call set.\
*'ex_bcftools'* is the call set generated using BCFTools with the WES (Whole exome sequencing) data. *'lc_bcftools'* is the call set generated using BCFTools with the low coverage WGS (whole genome sequencing) data. *'freebayes'* is the call set generated using Freebayes with the low coverage WGS+WES data. *'gatk'* is the call set generated using GATK UnifiedGenotyper with the low coverage WGS data. *'consensus'* is the final SNV call set generated after integrating the supporting call sets. Vertical bars show the size of the intersection between the call sets. Horizontal bars show the aggregated size of each call set. We used the filtered supporting call sets to generate this plot.](wellcomeopenres-4-17129-g0001){#f2}

![UpSet plot analysing the contribution of each of the four supporting call sets to the final INDEL consensus call set.\
*'ex_bcftools'* is the call set generated using BCFTools with the WES (Whole exome sequencing) data. *'lc_bcftools'* is the call set generated using BCFTools with the low coverage WGS (whole genome sequencing) data. *'freebayes'* is the call set generated using Freebayes with the low coverage WGS+WES data. *'gatk'* is the call set generated using GATK UnifiedGenotyper with the low coverage WGS data. *'consensus'* is the final INDEL call set generated after integrating the supporting call sets. Vertical bars show the size of the intersection between the call sets. Horizontal bars show the aggregated size of each call set. We used the filtered supporting call sets to generate this plot.](wellcomeopenres-4-17129-g0002){#f3}

***Switch error rate of the NA12878 sample***. In order to assess the phasing accuracy in our SNV and INDEL call set we estimated the switch error (SE) rate, which measures the rate for which the phase of a certain haplotype block is incorrectly predicted in the comparison with a true haplotype block. For example, if the correct haplotype is 000111\|111000 and the predicted haplotype is 00000\|111111, then we count one switch error between positions 3 and 4. In order to estimate these kind of errors we have used WhatsHap `‘compare’` (version 0.18) ^[@ref-20]^ with our phased variants for sample NA12878 and using the GIAB call set for this same sample as the gold-standard phased reference. The SE has been calculated for each autosome by using the following command for SNVs:

whatshap compare \--sample NA12878 \\ \--only-snvs NA12878.phased.GIAB.snps.chr\${i}.vcf.gz \\ combined.NA12878.phased.query.snps.chr\${i}.vcf.gz

And for INDELs:

whatshap compare \--sample NA12878 \\ NA12878.phased.GIAB.indels.chr\${i}.vcf.gz \\ combined.NA12878.phased.query.indels.chr\${i}.vcf.gz

We estimated the SE rates resulting from the following comparisons:

1.  our extended call set with GIAB on GRCh38

2.  lift-over call set with GIAB on GRCh38

3.  P3 call set with GIAB on GRCh37

And the results of these comparisons can be seen in [Table 5](#T5){ref-type="table"} for SNVs and [Table 6](#T6){ref-type="table"} for INDELs, where we can see that the average SE rate for SNVs across all the autosomes is lower in our call set (0.71%) than in the lift-over and P3 call sets (0.91% and 1.54% respectively) and is also lower for INDELs (1.78% versus 3.16% and 5.18% respectively).

###### Switch error (SE) rates for phased SNVs for NA12878.

*'This_work'* contains the rates for the comparison between our call set and GIAB. *'lift-over'* contains the rates for the lift-over call set compared to GIAB. *'P3'* column contains the rates for the phase three call set compared to GIAB.

  chromosome   This_work   lift-over   P3
  ------------ ----------- ----------- -----------
  **1**        0.99%       1.15%       2.42%
  **2**        0.53%       0.70%       0.70%
  **3**        0.48%       0.77%       0.72%
  **4**        0.50%       0.66%       2.45%
  **5**        0.51%       0.68%       2.30%
  **6**        1.40%       1.59%       2.35%
  **7**        0.74%       0.93%       1.23%
  **8**        0.61%       0.85%       2.16%
  **9**        0.43%       0.70%       2.36%
  **10**       0.89%       1.17%       1.49%
  **11**       0.57%       0.65%       2.50%
  **12**       0.44%       0.63%       0.65%
  **13**       0.44%       0.64%       0.66%
  **14**       0.44%       0.69%       0.68%
  **15**       0.61%       0.77%       0.77%
  **16**       1.17%       1.35%       0.60%
  **17**       1.62%       1.77%       0.82%
  **18**       0.53%       0.74%       2.38%
  **19**       0.37%       0.67%       2.94%
  **20**       0.46%       0.66%       0.59%
  **21**       0.44%       0.58%       0.57%
  **22**       1.52%       1.73%       2.53%
  **AVG**      **0.71%**   **0.91%**   **1.54%**

###### Switch error (SE) rates for phased INDELs from NA12878.

*'This_work'* contains the rates for the comparison between our call set and GIAB. *'lift-over'* contains the rates for the lift-over call set compared to GIAB. *'P3'* column contains the rates for the phase three call set compared to GIAB.

  chromosome   This_work   lift-over   P3
  ------------ ----------- ----------- -----------
  **1**        2.55%       4.85%       9.32%
  **2**        0.66%       1.29%       1.32%
  **3**        0.44%       1.25%       1.23%
  **4**        0.56%       0.93%       7.64%
  **5**        0.57%       1.16%       8.35%
  **6**        4.67%       7.10%       8.22%
  **7**        2.26%       3.26%       3.68%
  **8**        0.95%       2.34%       8.70%
  **9**        0.40%       1.51%       8.67%
  **10**       2.91%       4.55%       5.17%
  **11**       0.71%       0.99%       8.68%
  **12**       0.43%       1.12%       1.26%
  **13**       0.52%       0.89%       0.73%
  **14**       0.51%       1.18%       1.13%
  **15**       0.58%       1.12%       1.17%
  **16**       5.56%       9.14%       1.10%
  **17**       6.35%       10.74%      1.53%
  **18**       0.56%       1.24%       8.97%
  **19**       0.62%       2.01%       12.75%
  **20**       0.86%       1.65%       1.47%
  **21**       0.73%       1.15%       1.24%
  **22**       5.83%       10.04%      11.57%
  **AVG**      **1.78%**   **3.16%**   **5.18%**

Comparison with the Genome in a bottle (GIAB) call set for NA12878
------------------------------------------------------------------

***Biallelic SNVs***. To assess our biallelic SNV call set and compare it to the final phase of the 1000 Genomes Project, we utilised resources from GIAB. Our strategy compares our GRCh38 calls for NA12878 with the NA12878 calls on GRCh38 from GIAB. In addition, we compared the 1000 Genomes calls for NA12878 to those from GIAB on GRCh37. NA12878 was used in benchmarking as GIAB provides an independent gold-standard data set. For other samples in the 1000 Genomes Project panel, such data is not available, making meaningful benchmarking with other samples impossible. The use of a joint genotyping approach precludes applying our method to a single sample where high quality data is available but a population with low coverage and exome data is not. This limits suitable benchmarks to NA12878 and it should be noted that GIAB's analysis uses only the primary assembly in alignment, giving a different base from which to make calls, which may include reads that would otherwise have aligned to alt sequences. Within these limitations, this approach enables us to benchmark the performance with an independently produced gold-standard and allows us to apply the equivalent benchmark to data from the 1000 Genomes Project on GRCh37, indicating how our call set compares to that produced by the 1000 Genomes Project.

For NA12878, there are no indications that it is an outlier in the 1000 Genomes Project sequence data. It has similar coverage to other samples at 4.6x compared to an average of 6.2x (standard deviation 2.3) for the WGS and 144.1x relative to an average of 84.9x (standard deviation 34.1) for the exome data, and the same technologies are applied across the data set. Given the prevalence of NA12878 data, we would expect the callers to perform well with this sample but, as the NA12878 data in our work is not exceptional in the data set, we believe the results seen in benchmarking NA12878 are likely to broadly reflect performance across the data set.

We used the NA12878 variants from the multi-sample phased SNV-only VCF and compared them with the GIAB sites on GRCh38 downloaded from \[ <ftp://ftp-trace.ncbi.nlm.nih.gov/giab/ftp/release/NA12878_HG001/latest>\] (version 3.3.2). For GRCh37 we compared variants from the final phase of the 1000 Genomes Project (downloaded [here](ftp://ftp.1000genomes.ebi.ac.uk/vol1/ftp/release/20130502/)) with the GRCh37 GIAB variants obtained [here](ftp://ftp-trace.ncbi.nlm.nih.gov/giab/ftp/release/NA12878_HG001/latest/GRCh37/) (version 3.3.2). Our comparison is restricted to the regions in the autosomes and in the PAR region of chromosome X where GIAB considers calls to be high confidence (on average 77.9%, standard deviation 12.1%, of the bases for each of the chromosomes are in high confidence regions) and was performed using the Nextflow ^[@ref-21]^ workflow accessible from the link in the software availability section.

The result of our comparison is shown in [Table 7](#T7){ref-type="table"}. The average percentage of sites among all the chromosomes identified in our work that were also present in GIAB represents 96.4% of the total GIAB sites. This percentage is comparable to 97.9% resulting from the comparison with the final phase of the 1000 Genomes Project (phase three - P3). Additionally, the percentage of sites identified in our call set but not in GIAB is 0.5%, which is comparable to the 0.4% obtained in the comparison with 1000 Genomes phase three.

###### Site comparison for NA12878 between our call set and Genome in a Bottle (GIAB)-mapped to GRCh38 and between the 1000 Genomes Project phase three (P3) call set and GIAB mapped to GRCh37.

Results are shown for each chromosome. *'Shared (TP)'* are the true positive variants identified in the compared call sets. *'giab_only (FN)'* are the false negative variants identified by GIAB only. *'Thiswork_only (FP)'* are the false positive variants identified in our call set only.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------
  Dataset                                    Shared\       %shared\    giab_only\   %giab_only\   Thiswork_only\   %Thiswork_only\   Total\        Total\
                                             (TP)          (TP)        (FN)         (FN)          (FP)             (FP)              (GIAB)        thiswork_only
  ------------------------------------------ ------------- ----------- ------------ ------------- ---------------- ----------------- ------------- ---------------
  **Chr1**\                                  238,323       96.37       8,965        3.63          1,347            0.56              247,288       239,670
  **(b38)**                                                                                                                                        

  **Chr1**\                                  242,331       98.09       4,707        1.91          1,700            0.70              247,038       244,031
  **(b37)**                                                                                                                                        

  **Chr2**\                                  237,017       96.42       8,791        3.58          1,264            0.53              245,808       238,281
  **(b38)**                                                                                                                                        

  **Chr2**\                                  260,921       98.14       4,942        1.86          1,209            0.46              265,863       262,130
  **(b37)**                                                                                                                                        

  **Chr3**\                                  214,201       96.17       8,520        3.83          1,134            0.53              222,721       215,335
  **(b38)**                                                                                                                                        

  **Chr3**\                                  218,474       97.93       4,608        2.07          926              0.42              223,082       219,400
  **(b37)**                                                                                                                                        

  **Chr4**\                                  188,608       96.00       7,860        4.00          847              0.45              196,468       189,455
  **(b38)**                                                                                                                                        

  **Chr4**\                                  232,888       97.93       4,927        2.07          888              0.38              237,815       233,776
  **(b37)**                                                                                                                                        

  **Chr5**\                                  181,015       96.26       7,031        3.74          865              0.48              188,046       181,880
  **(b38)**                                                                                                                                        

  **Chr5**\                                  193,359       95.48       9,162        4.52          766              0.39              202,521       194,125
  **(b37)**                                                                                                                                        

  **Chr6**\                                  197,830       96.04       8,151        3.96          940              0.47              205,981       198,770
  **(b38)**                                                                                                                                        

  **Chr6**\                                  191,018       98.05       3,801        1.95          844              0.44              194,819       191,862
  **(b37)**                                                                                                                                        

  **Chr7**\                                  166,888       96.54       5,982        3.46          854              0.51              172,870       167,742
  **(b38)**                                                                                                                                        

  **Chr7**\                                  167,924       97.98       3,464        2.02          712              0.42              171,388       168,636
  **(b37)**                                                                                                                                        

  **Chr8**\                                  145,748       96.24       5,700        3.76          678              0.46              151,448       146,426
  **(b38)**                                                                                                                                        

  **Chr8**\                                  171,950       97.76       3,937        2.24          715              0.41              175,887       172,665
  **(b37)**                                                                                                                                        

  **Chr9**\                                  131,987       96.42       4,899        3.58          635              0.48              136,886       132,622
  **(b38)**                                                                                                                                        

  **Chr9**\                                  132,596       97.84       2,924        2.16          581              0.44              135,520       133,177
  **(b37)**                                                                                                                                        

  **Chr10**\                                 153,504       96.55       5,480        3.45          815              0.53              158,984       154,319
  **(b38)**                                                                                                                                        

  **Chr10**\                                 153,080       97.87       3,338        2.13          648              0.42              156,418       153,728
  **(b37)**                                                                                                                                        

  **Chr11**\                                 154,516       95.83       6,720        4.17          775              0.50              161,236       155,291
  **(b38)**                                                                                                                                        

  **Chr11**\                                 155,511       97.86       3,407        2.14          609              0.39              158,918       156,120
  **(b37)**                                                                                                                                        

  **Chr12**\                                 136,457       96.46       5,008        3.54          745              0.54              141,465       137,202
  **(b38)**                                                                                                                                        

  **Chr12**\                                 148,026       98.03       2,972        1.97          676              0.45              150,998       148,702
  **(b37)**                                                                                                                                        

  **Chr13**\                                 121,294       96.89       3,889        3.11          560              0.46              125,183       121,854
  **(b38)**                                                                                                                                        

  **Chr13**\                                 122,424       98.08       2,395        1.92          423              0.34              124,819       122,847
  **(b37)**                                                                                                                                        

  **Chr14**\                                 99,613        96.03       4,122        3.97          493              0.49              103,735       100,106
  **(b38)**                                                                                                                                        

  **Chr14**\                                 99,543        97.74       2,300        2.26          434              0.43              101,843       99,977
  **(b37)**                                                                                                                                        

  **Chr15**\                                 85,881        96.59       3,031        3.41          386              0.45              88,912        86,267
  **(b38)**                                                                                                                                        

  **Chr15**\                                 87,224        97.95       1,822        2.05          390              0.45              89,046        87,614
  **(b37)**                                                                                                                                        

  **Chr16**\                                 54,542        96.72       1,850        3.28          282              0.51              56,392        54,824
  **(b38)**                                                                                                                                        

  **Chr16**\                                 92,735        97.92       1,967        2.08          424              0.46              94,702        93,159
  **(b37)**                                                                                                                                        

  **Chr17**\                                 73,765        96.69       2,524        3.31          484              0.65              76,289        74,249
  **(b38)**                                                                                                                                        

  **Chr17**\                                 76,187        98.27       1,341        1.73          441              0.58              77,528        76,628
  **(b37)**                                                                                                                                        

  **Chr18**\                                 73,419        96.89       2,360        3.11          344              0.47              75,779        73,763
  **(b38)**                                                                                                                                        

  **Chr18**\                                 93,004        97.97       1,923        2.03          365              0.39              94,927        93,369
  **(b37)**                                                                                                                                        

  **Chr19**\                                 56,210        95.27       2,788        4.73          461              0.81              58,998        56,671
  **(b38)**                                                                                                                                        

  **Chr19**\                                 59,138        97.93       1,248        2.07          376              0.63              60,386        59,514
  **(b37)**                                                                                                                                        

  **Chr20**\                                 64,786        96.78       2,154        3.22          419              0.64              66,940        65,205
  **(b38)**                                                                                                                                        

  **Ch20**\                                  64,827        97.89       1,400        2.11          275              0.42              66,227        65,102
  **(b37)**                                                                                                                                        

  **Chr21**\                                 42,453        96.96       1,329        3.04          225              0.53              43,782        42,678
  **(b38)**                                                                                                                                        

  **Chr21**\                                 43,941        98.13       836          1.87          178              0.40              44,777        44,119
  **(b37)**                                                                                                                                        

  **Chr22**\                                 33,351        96.81       1,099        3.19          193              0.58              34,450        33,544
  **(b38)**                                                                                                                                        

  **Chr22**\                                 36,132        98.16       678          1.84          207              0.57              36,810        36,339
  **(b37)**                                                                                                                                        

  **ChrX**\                                  109           93.97       7            6.03          2                1.80              116           111
  **(b38) [\*](#TFN1){ref-type="other"}**                                                                                                          

  **AVG [\*\*](#TFN2){ref-type="other"}**\   **129,609**   **96.41**   **4,921**    **3.59**      **670**          **0.53**          **134,530**   **130,280**
  **(b38)**                                                                                                                                        

  **AVG**\                                   **138,329**   **97.86**   **3,095**    **2.14**      **627**          **0.45**          **141,424**   **138,955**
  **(b37)**                                                                                                                                        
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------

\* Only PAR regions

\*\* Not considering chrX for the calculation

***Biallelic SNVs and INDELs***. We also compared the extended call set containing SNVs and INDELs with the GIAB NA12878 call set in the same way that we did for our previous SNV-only call set (see above).

Additionally, we included the 1000 Genomes Project variants lifted to GRCh38 by dbSNP in the comparison with the GRCh38 GIAB sites. The lift-over call set used in this comparison is accessible from \[ftp:// [ftp.1000genomes.ebi.ac.uk/vol1/ftp/release/20130502/supporting/GRCh38_positions](http://ftp.1000genomes.ebi.ac.uk/vol1/ftp/release/20130502/supporting/GRCh38_positions)\]. The result of this comparison between our call set and the lift-over callset with GIAB on GRCh38 and between P3 and GIAB on GRCh37 can be seen in [Table 8](#T8){ref-type="table"} for the SNV sites and [Table 9](#T9){ref-type="table"} for the INDEL sites. Our integrated call set contains 96.4% of the total GIAB SNV sites. This percentage is similar to 97.9% resulting from the comparison with P3 and to 97.0% for the comparison between the lift-over and GIAB. Additionally, 0.5% of the SNV sites we identified were not in GIAB, similar to the 0.4% for P3 and to the 0.5% for the lift-over.

###### SNV-only site comparison for NA12878 between our call set and Genome in a Bottle (GIAB)-mapped to GRCh38, between the lift-over (chr\*\_L rows in the table) call set-mapped to GRCh38 and between the 1000 Genomes Project phase 3 (P3) call set and GIAB mapped to GRCh37.

Results are shown for each chromosome. ' *Shared (TP)*' are the true positive variants identified in the compared call sets. ' *giab_only (FN)*' are the false negative variants identified by GIAB only. ' *Thiswork_only (FP)*' are the false positive variants identified in our call set only.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------
  Dataset                                    Shared\       %shared\    giab_only\   %giab_only\   Thiswork_only\   %Thiswork_only\   Total\        Total\
                                             (TP)          (TP)        (FN)         (FN)          (FP)             (FP)              (GIAB)        thiswork_only
  ------------------------------------------ ------------- ----------- ------------ ------------- ---------------- ----------------- ------------- ---------------
  **Chr1**\                                  238,340       96.38       8,948        3.62          1,270            0.53              **247,288**   **239,610**
  **(b38)**                                                                                                                                        

  **Chr1_L**\                                241,396       97.62       5,892        2.38          1,799            0.74              **247,288**   **243,195**
  **(b38)**                                                                                                                                        

  **Chr1**\                                  242,331       98.09       4,707        1.91          1,700            0.7               **247,038**   **244,031**
  **(b37)**                                                                                                                                        

  **Chr2**\                                  237,055       96.44       8,753        3.56          1,208            0.51              **245,808**   **238,263**
  **(b38)**                                                                                                                                        

  **Chr2_L**\                                240,944       98.02       4,864        1.98          1,232            0.51              **245,808**   **242,176**
  **(b38)**                                                                                                                                        

  **Chr2**\                                  260,921       98.14       4,942        1.86          1,209            0.46              **265,863**   **262,130**
  **(b37)**                                                                                                                                        

  **Chr3**\                                  214,315       96.23       8,406        3.77          1,027            0.48              **222,721**   **215,342**
  **(b38)**                                                                                                                                        

  **Chr3_L**\                                217,446       97.63       5,275        2.37          1,061            0.49              **222,721**   **218,507**
  **(b38)**                                                                                                                                        

  **Chr3**\                                  218,474       97.93       4,608        2.07          926              0.42              **223,082**   **219,400**
  **(b37)**                                                                                                                                        

  **Chr4**\                                  188,516       95.95       7,952        4.05          873              0.46              **196,468**   **189,389**
  **(b38)**                                                                                                                                        

  **Chr4_L**\                                192,186       97.82       4,282        2.18          761              0.39              **196,468**   **192,947**
  **(b38)**                                                                                                                                        

  **Chr4**\                                  232,888       97.93       4,927        2.07          888              0.38              **237,815**   **233,776**
  **(b37)**                                                                                                                                        

  **Chr5**\                                  180,892       96.2        7,154        3.8           903              0.5               **188,046**   **181,795**
  **(b38)**                                                                                                                                        

  **Chr5_L**\                                179,468       95.44       8,578        4.56          756              0.42              **188,046**   **180,224**
  **(b38)**                                                                                                                                        

  **Chr5**\                                  193,359       95.48       9,162        4.52          766              0.39              **202,521**   **194,125**
  **(b37)**                                                                                                                                        

  **Chr6**\                                  197,693       95.98       8,288        4.02          1,013            0.51              **205,981**   **198,706**
  **(b38)**                                                                                                                                        

  **Chr6_L**\                                199,172       96.69       6,809        3.31          1,150            0.57              **205,981**   **200,322**
  **(b38)**                                                                                                                                        

  **Chr6**\                                  191,018       98.05       3,801        1.95          844              0.44              **194,819**   **191,862**
  **(b37)**                                                                                                                                        

  **Chr7**\                                  166,777       96.48       6,093        3.52          895              0.53              **172,870**   **167,672**
  **(b38)**                                                                                                                                        

  **Chr7_L**\                                168,159       97.27       4,711        2.73          793              0.47              **172,870**   **168,952**
  **(b38)**                                                                                                                                        

  **Chr7**\                                  167,924       97.98       3,464        2.02          712              0.42              **171,388**   **168,636**
  **(b37)**                                                                                                                                        

  **Chr8**\                                  145,659       96.18       5,789        3.82          719              0.49              **151,448**   **146,378**
  **(b38)**                                                                                                                                        

  **Chr8_L**\                                147,895       97.65       3,553        2.35          665              0.45              **151,448**   **148,560**
  **(b38)**                                                                                                                                        

  **Chr8**\                                  171,950       97.76       3,937        2.24          715              0.41              **175,887**   **172,665**
  **(b37)**                                                                                                                                        

  **Chr9**\                                  131,911       96.37       4,975        3.63          678              0.51              **136,886**   **132,589**
  **(b38)**                                                                                                                                        

  **Chr9_L**\                                133,365       97.43       3,521        2.57          614              0.46              **136,886**   **133,979**
  **(b38)**                                                                                                                                        

  **Chr9**\                                  132,596       97.84       2,924        2.16          581              0.44              **135,520**   **133,177**
  **(b37)**                                                                                                                                        

  **Chr10**\                                 153,422       96.5        5,562        3.5           853              0.55              **158,984**   **154,275**
  **(b38)**                                                                                                                                        

  **Chr10_L**\                               153,010       96.24       5,974        3.76          699              0.45              **158,984**   **153,709**
  **(b38)**                                                                                                                                        

  **Chr10**\                                 153,080       97.87       3,338        2.13          648              0.42              **156,418**   **153,728**
  **(b37)**                                                                                                                                        

  **Chr11**\                                 154,414       95.77       6,822        4.23          808              0.52              **161,236**   **155,222**
  **(b38)**                                                                                                                                        

  **Chr11_L**\                               156,330       96.96       4,906        3.04          717              0.46              **161,236**   **157,047**
  **(b38)**                                                                                                                                        

  **Chr11**\                                 155,511       97.86       3,407        2.14          609              0.39              **158,918**   **156,120**
  **(b37)**                                                                                                                                        

  **Chr12**\                                 136,392       96.41       5,073        3.59          771              0.56              **141,465**   **137,163**
  **(b38)**                                                                                                                                        

  **Chr12_L**\                               135,131       95.52       6,334        4.48          646              0.48              **141,465**   **135,777**
  **(b38)**                                                                                                                                        

  **Chr12**\                                 148,026       98.03       2,972        1.97          676              0.45              **150,998**   **148,702**
  **(b37)**                                                                                                                                        

  **Chr13**\                                 121,218       96.83       3,965        3.17          588              0.48              **125,183**   **121,806**
  **(b38)**                                                                                                                                        

  **Chr13_L**\                               122,714       98.03       2,469        1.97          475              0.39              **125,183**   **123,189**
  **(b38)**                                                                                                                                        

  **Chr13**\                                 122,424       98.08       2,395        1.92          423              0.34              **124,819**   **122,847**
  **(b37)**                                                                                                                                        

  **Chr14**\                                 99,551        95.97       4,184        4.03          501              0.5               **103,735**   **100,052**
  **(b38)**                                                                                                                                        

  **Chr14_L**\                               99,210        95.64       4,525        4.36          501              0.5               **103,735**   **99,711**
  **(b38)**                                                                                                                                        

  **Chr14**\                                 99,543        97.74       2,300        2.26          434              0.43              **101,843**   **99,977**
  **(b37)**                                                                                                                                        

  **Chr15**\                                 85,827        96.53       3,085        3.47          421              0.49              **88,912**    **86,248**
  **(b38)**                                                                                                                                        

  **Chr15_L**\                               86,887        97.72       2,025        2.28          426              0.49              **88,912**    **87,313**
  **(b38)**                                                                                                                                        

  **Chr15**\                                 87,224        97.95       1,822        2.05          390              0.45              **89,046**    **87,614**
  **(b37)**                                                                                                                                        

  **Chr16**\                                 54,517        96.68       1,875        3.32          285              0.52              **56,392**    **54,802**
  **(b38)**                                                                                                                                        

  **Chr16_L**\                               55,233        97.94       1,159        2.06          264              0.48              **56,392**    **55,497**
  **(b38)**                                                                                                                                        

  **Chr16**\                                 92,735        97.92       1,967        2.08          424              0.46              **94,702**    **93,159**
  **(b37)**                                                                                                                                        

  **Chr17**\                                 73,701        96.61       2,588        3.39          502              0.68              **76,289**    **74,203**
  **(b38)**                                                                                                                                        

  **Chr17_L**\                               73,299        96.08       2,990        3.92          460              0.62              **76,289**    **73,759**
  **(b38)**                                                                                                                                        

  **Chr17**\                                 76,187        98.27       1,341        1.73          441              0.58              **77,528**    **76,628**
  **(b37)**                                                                                                                                        

  **Chr18**\                                 73,375        96.83       2,404        3.17          371              0.5               **75,779**    **73,746**
  **(b38)**                                                                                                                                        

  **Chr18_L**\                               74,194        97.91       1,585        2.09          295              0.4               **75,779**    **74,489**
  **(b38)**                                                                                                                                        

  **Chr18**\                                 93,004        97.97       1,923        2.03          365              0.39              **94,927**    **93,369**
  **(b37)**                                                                                                                                        

  **Chr19**\                                 56,171        95.21       2,827        4.79          480              0.85              **58,998**    **56,651**
  **(b38)**                                                                                                                                        

  **Chr19_L**\                               55,897        94.74       3,101        5.26          422              0.75              **58,998**    **56,319**
  **(b38)**                                                                                                                                        

  **Chr19**\                                 59,138        97.93       1,248        2.07          376              0.63              **60,386**    **59,514**
  **(b37)**                                                                                                                                        

  **Chr20**\                                 64,800        96.8        2,140        3.2           399              0.61              **66,940**    **65,199**
  **(b38)**                                                                                                                                        

  **Chr20_L**\                               65,006        97.11       1,934        2.89          335              0.51              **66,940**    **65,341**
  **(b38)**                                                                                                                                        

  **Ch20**\                                  64,827        97.89       1,400        2.11          275              0.42              **66,227**    **65,102**
  **(b37)**                                                                                                                                        

  **Chr21**\                                 42,433        96.92       1,349        3.08          229              0.54              **43,782**    **42,662**
  **(b38)**                                                                                                                                        

  **Chr21_L**\                               42,830        97.83       952          2.17          197              0.46              **43,782**    **43,027**
  **(b38)**                                                                                                                                        

  **Chr21**\                                 43,941        98.13       836          1.87          178              0.4               **44,777**    **44,119**
  **(b37)**                                                                                                                                        

  **Chr22**\                                 33,336        96.77       1,114        3.23          209              0.62              **34,450**    **33,545**
  **(b38)**                                                                                                                                        

  **Chr22_L**\                               33,418        97          1,032        3             209              0.62              **34,450**    **33,627**
  **(b38)**                                                                                                                                        

  **Chr22**\                                 36,132        98.16       678          1.84          207              0.57              **36,810**    **36,339**
  **(b37)**                                                                                                                                        

  **ChrX**\                                  112           96.55       4            3.45          2                1.75              **116**       **114**
  **(b38) [\*](#TFN3){ref-type="other"}**                                                                                                          

  **AVG [\*\*](#TFN4){ref-type="other"}**\   **129,560**   **96.37**   **4,970**    **3.63**      **682**          **0.54**          **134,530**   **130,242**
  **(b38)**                                                                                                                                        

  **AVG [\*\*](#TFN4){ref-type="other"}**\   **130,600**   **97.01**   **3,931**    **2.99**      **658**          **0.51**          **134,530**   **131,258**
  **(b38\_**\                                                                                                                                      
  **lifted)**                                                                                                                                      

  **AVG [\*\*](#TFN4){ref-type="other"}**\   **138,329**   **97.86**   **3,095**    **2.14**      **627**          **0.45**          **141,424**   **138,955**
  **(b37)**                                                                                                                                        
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------

\* Only PAR regions

\*\* Not considering chrX for the calculation

###### INDEL site comparison for NA12878 between our call set and Genome in a Bottle (GIAB)-mapped to GRCh38, between the lift-over (chr\*\_L rows in the table) call set-mapped to GRCh38 and between the 1000 Genomes Project phase three (P3) call set and GIAB mapped to GRCh37.

Results are shown for each chromosome. *'Shared (TP)'* are the true positive variants identified in the compared call sets. *'giab_only (FN)'* are the false negative variants identified by GIAB only. *'Thiswork_only (FP)'* are the false positive variants identified in our call set only.

  --------------------------------------------------------------------------------------------------------------------------------------
  Dataset         shared\      \% shared\   giab_only\   \% giab_only\   Thiswork_only\   %Thiswork_only\   Total\       Total\
                  (TP)         (TP)         (FN)         (FN)            (FP)             (FP)              (GIAB)       thiswork_only
  --------------- ------------ ------------ ------------ --------------- ---------------- ----------------- ------------ ---------------
  **Chr1**\       24,659       63.86        13,954       36.14           3,143            11.30             38,613       27,802
  **(b38)**                                                                                                              

  **Chr1_L**\     27,009       69.95        11,604       30.05           2,261            7.72              38,613       29,270
  **(b38)**                                                                                                              

  **Chr1**\       25,802       73.03        9,530        26.97           2,171            7.76              35,332       27,973
  **(b37)**                                                                                                              

  **Chr2**\       24,237       65.05        13,023       34.95           2,995            11.00             37,260       27,232
  **(b38)**                                                                                                              

  **Chr2_L**\     26,504       71.13        10,756       28.87           2,132            7.45              37,260       28,636
  **(b38)**                                                                                                              

  **Chr2**\       26,856       73.46        9,702        26.54           2,146            7.40              36,558       29,002
  **(b37)**                                                                                                              

  **Chr3**\       21,768       64.95        11,745       35.05           2,530            10.41             33,513       24,298
  **(b38)**                                                                                                              

  **Chr3_L**\     23,830       71.11        9,683        28.89           1,762            6.88              33,513       25,592
  **(b38)**                                                                                                              

  **Chr3**\       22,495       73.94        7,930        26.06           1,693            7.00              30,425       24,188
  **(b37)**                                                                                                              

  **Chr4**\       19,675       68.14        9,200        31.86           2,303            10.48             28,875       21,978
  **(b38)**                                                                                                              

  **Chr4\_**\     21,190       73.39        7,684        26.61           1,460            6.45              28,874       22,650
  **(b38)**                                                                                                              

  **Chr4**\       24,275       75.40        7,921        24.60           1,694            6.52              32,196       25,969
  **(b37)**                                                                                                              

  **Chr5**\       18,558       65.74        9,673        34.26           2,202            10.61             28,231       20,760
  **(b38)**                                                                                                              

  **Chr5_L**\     20,330       72.01        7,901        27.99           1,436            6.60              28,231       21,766
  **(b38)**                                                                                                              

  **Chr5**\       20,813       74.15        7,255        25.85           1,502            6.73              28,068       22,315
  **(b37)**                                                                                                              

  **Chr6**\       20,711       65.73        10,797       34.27           2,521            10.85             31,508       23,232
  **(b38)**                                                                                                              

  **Chr6_L**\     22,394       71.07        9,114        28.93           1,647            6.85              31,508       24,041
  **(b38)**                                                                                                              

  **Chr6**\       20,488       74.09        7,163        25.91           1,478            6.73              27,651       21,966
  **(b37)**                                                                                                              

  **Chr7**\       17,069       64.38        9,444        35.62           2,129            11.09             26,513       19,198
  **(b38)**                                                                                                              

  **Chr7_L**\     18,112       68.31        8,401        31.69           1,389            7.12              26,513       19,501
  **(b38)**                                                                                                              

  **Chr7**\       17,058       71.70        6,732        28.30           1,354            7.35              23,790       18,412
  **(b37)**                                                                                                              

  **Chr8**\       14,387       64.00        8,093        36.00           1,761            10.91             22,480       16,148
  **(b38)**                                                                                                              

  **Chr8_L**\     15,467       68.80        7,013        31.20           1,147            6.90              22,480       16,614
  **(b38)**                                                                                                              

  **Chr8**\       16,164       71.64        6,400        28.36           1,207            6.95              22,564       17,371
  **(b37)**                                                                                                              

  **Chr9**\       12,410       64.04        6,969        35.96           1,547            11.08             19,379       13,957
  **(b38)**                                                                                                              

  **Chr9_L**\     13,476       69.54        5,903        30.46           1,149            7.86              19,379       14,625
  **(b38)**                                                                                                              

  **Chr9**\       12,691       72.88        4,722        27.12           1,058            7.70              17,413       13,749
  **(b37)**                                                                                                              

  **Chr10**\      15,506       64.61        8,492        35.39           1,987            11.36             23,998       17,493
  **(b38)**                                                                                                              

  **Chr10_L**\    16,771       69.88        7,227        30.12           1,341            7.40              23,998       18,112
  **(b38)**                                                                                                              

  **Chr10**\      15,961       73.18        5,850        26.82           1,285            7.45              21,811       17,246
  **(b37)**                                                                                                              

  **Chr11**\      15,605       66.40        7,898        33.60           1,845            10.57             23,503       17,450
  **(b38)**                                                                                                              

  **Chr11_L**\    17,013       72.39        6,490        27.61           1,266            6.93              23,503       18,279
  **(b38)**                                                                                                              

  **Chr11**\      16,071       75.63        5,179        24.37           1,208            6.99              21,250       17,279
  **(b37)**                                                                                                              

  **Chr12**\      14,366       63.28        8,335        36.72           1,854            11.43             22,701       16,220
  **(b38)**                                                                                                              

  **Chr12_L**\    15,608       68.75        7,093        31.25           1,275            7.55              22,701       16,883
  **(b38)**                                                                                                              

  **Chr12**\      16,042       73.25        5,859        26.75           1,334            7.68              21,901       17,376
  **(b37)**                                                                                                              

  **Chr13**\      12,631       68.28        5,869        31.72           1,485            10.52             18,500       14,116
  **(b38)**                                                                                                              

  **Chr13_L**\    13,634       73.70        4,866        26.30           1,039            7.08              18,500       14,673
  **(b38)**                                                                                                              

  **Chr13**\      12,990       76.03        4,096        23.97           970              6.95              17,086       13,960
  **(b37)**                                                                                                              

  **Chr14**\      10,344       64.71        5,640        35.29           1,338            11.45             15,984       11,682
  **(b38)**                                                                                                              

  **Chr14_L**\    11,268       70.50        4,716        29.50           1,024            8.33              15,984       12,292
  **(b38)**                                                                                                              

  **Chr14**\      10,764       74.57        3,670        25.43           896              7.68              14,434       11,660
  **(b37)**                                                                                                              

  **Chr15**\      8,770        64.28        4,874        35.72           1,052            10.71             13,644       9,822
  **(b38)**                                                                                                              

  **Chr15_L**\    9,746        71.43        3,898        28.57           792              7.52              13,644       10,538
  **(b38)**                                                                                                              

  **Chr15**\      9,265        74.66        3,145        25.34           728              7.29              12,410       9,993
  **(b37)**                                                                                                              

  **Chr16**\      4,662        61.17        2,959        38.83           704              13.12             7,621        5,366
  **(b38)**                                                                                                              

  **Chr16_L**\    5,233        68.67        2,388        31.33           520              9.04              7,621        5,753
  **(b38)**                                                                                                              

  **Chr16**\      8,409        70.44        3,529        29.56           837              9.05              11,938       9,246
  **(b37)**                                                                                                              

  **Chr17**\      8,053        60.29        5,303        39.71           1,136            12.36             13,356       9,189
  **(b38)**                                                                                                              

  **Chr17_L**\    8,977        67.21        4,379        32.79           867              8.81              13,356       9,844
  **(b38)**                                                                                                              

  **Chr17**\      8,866        70.94        3,632        29.06           828              8.54              12,498       9,694
  **(b37)**                                                                                                              

  **Chr18**\      7,618        67.20        3,718        32.80           928              10.86             11,336       8,546
  **(b38)**                                                                                                              

  **Chr18_L**\    7,915        69.82        3,421        30.18           581              6.84              11,336       8,496
  **(b38)**                                                                                                              

  **Chr18**\      9,482        72.12        3,666        27.88           689              6.77              13,148       10,171
  **(b37)**                                                                                                              

  **Chr19**\      6,090        56.81        4,630        43.19           896              12.83             10,720       6,986
  **(b38)**                                                                                                              

  **Chr19_L**\    6,620        61.75        4,100        38.25           694              9.49              10,720       7,314
  **(b38)**                                                                                                              

  **Chr19**\      6,638        66.14        3,398        33.86           701              9.55              10,036       7,339
  **(b37)**                                                                                                              

  **Chr20**\      6,430        62.55        3,849        37.45           823              11.35             10,279       7,253
  **(b38)**                                                                                                              

  **Chr20_L**\    6,744        65.61        3,535        34.39           559              7.65              10,279       7,303
  **(b38)**                                                                                                              

  **Ch20**\       6,435        68.82        2,915        31.18           528              7.58              9,350        6,963
  **(b37)**                                                                                                              

  **Chr21**\      4,752        67.60        2,278        32.40           547              10.32             7,030        5,299
  **(b38)**                                                                                                              

  **Chr21_L**\    5,144        73.17        1,886        26.83           350              6.37              7,030        5,494
  **(b38)**                                                                                                              

  **Chr21**\      5,104        76.49        1,569        23.51           330              6.07              6,673        5,434
  **(b37)**                                                                                                              

  **Chr22**\      3,399        60.02        2,264        39.98           479              12.35             5,663        3,878
  **(b38)**                                                                                                              

  **Chr22_L**\    3,764        66.48        1,898        33.52           353              8.57              5,662        4,117
  **(b38)**                                                                                                              

  **Chr22**\      4,072        69.91        1,753        30.09           362              8.16              5,825        4,434
  **(b37)**                                                                                                              

  **ChrX**\       15           53.57        13           46.43           5                25.00             28           20
  **(b38)\***                                                                                                            

  **AVG\*\***\    **13,259**   **64.23**    **7,228**    **35.77**       **1,646**        **11.23**         **20,487**   **14,905**
  **(b38)**                                                                                                              

  **AVG\*\***\    **14,398**   **69.76**    **6,089**    **30.24**       **1,138**        **7.52**          **20,487**   **15,536**
  **(b38**\                                                                                                              
  **\_lifted)**                                                                                                          

  **AVG\*\***\    **14,397**   **72.84**    **5,255**    **27.16**       **1,136**        **7.45**          **19,653**   **15,534**
  **(b37)**                                                                                                              
  --------------------------------------------------------------------------------------------------------------------------------------

\* Only PAR regions

\*\* Not considering chrX for the calculation

In order to characterize the profile of the GIAB NA12878 SNV sites that were missing in our call set but were present in the lift-over call set, we examined if we had evidence in any of our intermediate files of the presence of these sites, and if so, we looked for an explanation for these sites being discarded. The result of this analysis is shown in [Table 10](#T10){ref-type="table"}, where we can see that most of the sites that were missing (68.7% on average across all the autosomes) were discarded because of the filtering sensitivity cutoff used with VQSR ApplyRecalibrator ( `--ts_filter_level 99.5`) during the final filtering step of the consensus call set.

In the case of INDELs, we identified on average 64.2% of the INDEL sites that are also present in GIAB. This percentage is lower than the 73% obtained for the comparison between P3 and GIAB and lower than the 69.8% for the comparison of the lift-over with GIAB. This is possibly due to the fact that P3 used a higher number of algorithms specialized in the identification of INDELs than the ones used in this work

###### Analysis of the number of GIAB NA12878 SNV sites present in the lift-over call set not identified in our call set.

'False negatives' column contains the count of GIAB NA12878 SNV sites that were identified in the lift-over call set and not in our work. 'VQSRTrancheSNP99.50to99.9' column contains the count of false negative sites that were filtered out in our work assigned to the 99.5-99.9 quality tranche by VQSR. 'VQSRTrancheSNP99.90to100.0' column contains the count of false negative sites that were filtered out in our work assigned to the 99.9-100.0 quality tranche by VQSR. The higher the tranche, the higher the sensitivity and the lower the specificity of our call set. '% explained' column contains the percentage of false negatives that were discarded in our work by the VQSR filtering procedure.

  Dataset     False negatives   VQSRTrancheSNP99.50to99.90   VQSRTrancheSNP99.90to100.00   \% explained
  ----------- ----------------- ---------------------------- ----------------------------- --------------
  **Chr1**    5,224             3,666                        138                           72.82
  **Chr2**    5,071             3,476                        75                            70.03
  **Chr3**    4,635             3,198                        92                            70.98
  **Chr4**    4,592             3,274                        98                            73.43
  **Chr5**    3,949             2,808                        66                            72.78
  **Chr6**    4,916             3,489                        123                           73.47
  **Chr7**    3,462             2,338                        78                            69.79
  **Chr8**    3,246             2,155                        65                            68.39
  **Chr9**    2,652             1,750                        42                            67.57
  **Chr10**   2,893             1,870                        64                            66.85
  **Chr11**   3,896             2,768                        91                            73.38
  **Chr12**   2,802             1,937                        69                            71.59
  **Chr13**   2,024             1,261                        32                            63.88
  **Chr14**   2,177             1,463                        48                            69.41
  **Chr15**   1,643             1,028                        33                            64.58
  **Chr16**   977               528                          17                            55.78
  **Chr17**   1,359             835                          37                            64.16
  **Chr18**   1,261             821                          25                            67.09
  **Chr19**   1,401             929                          38                            69.02
  **Chr20**   1,051             623                          18                            60.99
  **Chr21**   728               477                          10                            66.9
  **Chr22**   628               477                          10                            77.55
  **AVG %**   2,753.95          1,871.41                     57.68                         68.66

Comparison of updated clinical loci
-----------------------------------

We further compared our call set and the lift-over call set in the regions identified by Schneider *et al*. ^[@ref-3]^ with assembly updates in GRCh38. The authors looked at the intersection of the transcripts having problems in the alignment with GRCh37 with two lists of clinically relevant genes: a set of genes enriched for *de novo* loss of function mutations identified in Autism Spectrum Disorder (n = 1003) ^[@ref-22]^ and a collection of genes preliminarily proposed for the development of a medical exome kit (n = 4623) ( <https://www.genomeweb.com/diagnostics/emory-chop-harvard-develop-medical-exome-complete-coverage-5k-disease-associated-genes>). Schneider *et al*. ^[@ref-3]^ show in their analysis that there were 14 genes from these two lists for which the alignment issues disappear when GRCh38 is used (see [Table 11](#T11){ref-type="table"}). Unsurprisingly, when viewing these regions, we see an absence of variation in the lift-over while calls have been made in the *de novo* analysis. This is illustrated in [Figure 4](#f4){ref-type="fig"}.

![Variants in regions containing clinically relevant genes that had coding sequence splits over assembly gaps in GRCh37 that have been filled in GRCh38.\
' *1KG native*': call set presented in this work; ' *1KG All SNPs/indels*': lift-over call set.](wellcomeopenres-4-17129-g0003){#f4}

###### Autism Spectrum Disorder genes [@ref-22] and Medical Exome Kit Genes ( <https://www.genomeweb.com/sequencing/emory-chop-harvard-develop-medical-exomekit-complete-coverage-5k-disease-associ>) that had transcript alignment issues with GRCh37 but not with GRCh38.

RefSeq release version 71. ' *True*' indicates presence in the relevant gene list. ' *False*' indicates absence.

  GeneID      GeneSymbol   MedicalExome   \[ [@ref-22]\]
  ----------- ------------ -------------- ----------------
  984         CDK11B       False          True
  10320       IKZF1        True           True
  3635        INPP5D       True           True
  3800        KIF5C        False          True
  102724631   POTEB3       False          True
  23380       SRGAP2       False          True
  1804        DPP6         True           False
  100134444   KCNJ18       True           False
  5645        PRSS2        True           False
  374462      PTPRQ        True           False
  259291      TAS2R45      True           False
  283953      TMEM114      True           False
  117581      TWIST2       True           False

Novel GRCh38 contigs
--------------------

We have also analysed the number of SNV variants located in the new contigs added to GRCh38 to update sequence or fill gaps present in GRCh37. The coordinates for these new contigs were obtained using UCSC's table browser ^[@ref-23]^, retrieving the data for the `Hg19Diff` track from the `hg38ContigDiff` primary table. Only the records having a score=0, which correspond to the coordinates of the new contigs added to GRCh38 to update sequence or fill gaps present in GRCh37 were considered. [Table 12](#T12){ref-type="table"} shows the comparison of the number of SNVs identified in the new contigs with the number in regions that were already present in GRCh37. We can see in these tables that the percentage of SNVs in the new GRCh38 contigs is higher in our call set (55.7% vs 44.3%) than in the lift-over call set, whereas the percentage is lower (48% vs 52%) for the rest of the genome.

###### Number of biallelic SNVs in our call set (' *This_work*') and in the ' *Lift-over*' call set.

' *novel*' represent the new contigs added to GRCh38 whereas ' *existing*' represent the rest of the genomic regions that were already present in GRCh37.

  Region         This_work           Lift-over          Total
  -------------- ------------------- ------------------ --------------------
  **novel**      1,019,976 (55.7%)   811,817 (44.3%)    1,831,793 (100%)
  **existing**   70,809,835 (48%)    76,588,820 (52%)   147,398,655 (100%)

***Concordance with Genome in a bottle (GIAB) NA12878 in novel regions***. We have also examined the overlap for biallelic SNV sites identified in sample NA12878 between the GIAB sites on the new GRCh38 contigs, our call set and the lift-over call set. [Figure 5](#f5){ref-type="fig"} has a barplot with the percentage of sites overlapping with GIAB and we can see that this percentage is greater in our call set in all the autosomes except chromosome 14, reaching percentages of 90% in our call set and only 9% in the lift-over call set for chromosome 10. This demonstrates that calling directly on GRCh38 can produce calls that are more reliable than a lift-over for novel regions.

![Percentage of SNVs that are true positives in the comparison with the NA12878 call set from GIAB for contigs added to GRCh38 across the different autosomes.\
' *TP_igsr*' is the percentage of true positives for our call set. ' *TP_liftover*' is the percentage of true positives for the lift-over call set.](wellcomeopenres-4-17129-g0004){#f5}

Call set performance summary
----------------------------

The benchmarking results show that, unsurprisingly, given the breadth of callers and extensive integration and filtering work, that phase three of 1000 Genomes Project performed best in comparison to GIAB on GRCh37. Further, we see only slightly diminished performance from the lift-over, when judging on genome wide metrics. Given that only some regions of the primary assembly have altered and that the benchmark (GIAB), like the original data set, does not interact with the alts, this may also not be wholly surprising. This picture, however, does change when looking in detail at improved regions of the assembly. Here, as expected, we see regions where the liftover contains no calls, because the sequence was not in GRCh37 and, therefore, could not possibly be called on - although our work demonstrates that calls are made.

In assessing the *de novo* call set, it seems that the reduced range of callers and simplified methodology, combined with a conservative filtering approach, mean that, relative to phase three, the GRCh38 *de novo* call set has slightly reduced sensitivity. However, its performance is of a similar order to those of the original phase three call set and the lift-over, while providing a consistent analysis of the data across the improved assembly, including some clinically significant novel regions where calls were not previously made.

As sequencing has progressed since the 1000 Genomes Project, it is also interesting to compare to modern data types. We looked at the calls recently released by the New York Genome Center (NYGC) for NA12878 which are part of a GATK HaplotypeCaller call set for the 2504 member phase three panel, which has been resequenced to 30x coverage ( <http://ftp.1000genomes.ebi.ac.uk/vol1/ftp/data_collections/1000G_2504_high_coverage/>). We retrieved the NA12878 calls and compared them to the GIAB GRCh38 call set. The average percentage of SNV sites identified by GATK HC in the high coverage data across all the chromosomes that were also present in GIAB represents 94.2% of the total GIAB sites, which is slightly lower than the 96.4% obtained in our work. In the case of INDEL sites, GATK HC identified an average of 42.1% of the total GIAB INDEL sites, which is lower than the 64.2% that we obtained for our call set. We anticipate that, as analysis of the high coverage data progresses, those outputs will replace the work described here but note that our approach achieves comparable results to those of a modern production pipeline.

Data availability
=================

The variants resulting from this work are available in the European Variation Archive. Accession number [PRJEB31735](https://www.ebi.ac.uk/eva/?eva-study=PRJEB31735).

This call set is also available from the International Genome Sample Resource (IGSR) ^[@ref-4]^ at: <http://ftp.1000genomes.ebi.ac.uk/vol1/ftp/data_collections/1000_genomes_project/release/20190312_biallelic_SNV_and_INDEL/>.

Software availability
=====================

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Task                Codebase                                                                                                                                     Documentation                                                                                                                        Licence                                                  DOI                                                                                                                           Ref.
  ------------------- -------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------ -------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------- -----------
  **eHive**\          [https://github.com/](https://github.com/Ensembl/ensembl-hive)\                                                                              [https://ensembl-hive.](https://ensembl-hive.readthedocs.io/en/version-2.5/)\                                                        [Apache](https://www.apache.org/licenses/LICENSE-2.0)\   NA                                                                                                                            [@ref-17]
  **(workflow**\      [Ensembl/ensembl-hive](https://github.com/Ensembl/ensembl-hive)                                                                              [readthedocs.io/en/](https://ensembl-hive.readthedocs.io/en/version-2.5/)\                                                           [2.0](https://www.apache.org/licenses/LICENSE-2.0)                                                                                                                                     
  **system)**                                                                                                                                                      [version-2.5/](https://ensembl-hive.readthedocs.io/en/version-2.5/)                                                                                                                                                                                                                                                         

  **BAM quality**\    [https://github.com/igsr/igsr\_](https://github.com/igsr/igsr_analysis/tree/v1.0.0/PyHive/BamQC)\                                            **WGS BAM QC:** [https://](https://igsr-analysis.readthedocs.io/en/latest/workflows/wgs_bamqc_pipeline.html)\                        [Apache](https://www.apache.org/licenses/LICENSE-2.0)\   [http://doi.org/10.5281/](http://doi.org/10.5281/zenodo.2573911)\                                                             [@ref-18]
  **control**         [analysis/tree/v1.0.0/PyHive/](https://github.com/igsr/igsr_analysis/tree/v1.0.0/PyHive/BamQC)\                                              [igsr-analysis.readthedocs.](https://igsr-analysis.readthedocs.io/en/latest/workflows/wgs_bamqc_pipeline.html)\                      [2.0](https://www.apache.org/licenses/LICENSE-2.0)       [zenodo.2573911](http://doi.org/10.5281/zenodo.2573911)                                                                       
                      [BamQC](https://github.com/igsr/igsr_analysis/tree/v1.0.0/PyHive/BamQC)                                                                      [io/en/latest/workflows/](https://igsr-analysis.readthedocs.io/en/latest/workflows/wgs_bamqc_pipeline.html)\                                                                                                                                                                                                                
                                                                                                                                                                   [wgs_bamqc_pipeline.html](https://igsr-analysis.readthedocs.io/en/latest/workflows/wgs_bamqc_pipeline.html)\                                                                                                                                                                                                                
                                                                                                                                                                   \                                                                                                                                                                                                                                                                                                                           
                                                                                                                                                                   **WES BAM QC:** [https://](https://igsr-analysis.readthedocs.io/en/latest/workflows/wes_bamqc_pipeline.html)\                                                                                                                                                                                                               
                                                                                                                                                                   [igsr-analysis.readthedocs.](https://igsr-analysis.readthedocs.io/en/latest/workflows/wes_bamqc_pipeline.html)\                                                                                                                                                                                                             
                                                                                                                                                                   [io/en/latest/workflows/](https://igsr-analysis.readthedocs.io/en/latest/workflows/wes_bamqc_pipeline.html)\                                                                                                                                                                                                                
                                                                                                                                                                   [wes_bamqc_pipeline.html](https://igsr-analysis.readthedocs.io/en/latest/workflows/wes_bamqc_pipeline.html)                                                                                                                                                                                                                 

  **Variant**\        [https://github.com/EMBL-](https://github.com/EMBL-EBI-GCA/reseqtrack/tree/master/modules/ReseqTrack/Hive)\                                  [https://github.com/EMBL-](https://github.com/EMBL-EBI-GCA/reseqtrack/blob/master/docs/variantcalling_pipeline.txt)\                 [Apache](https://www.apache.org/licenses/LICENSE-2.0)\   [https://doi.org/10.5281/](https://doi.org/10.5281/zenodo.2573969) [zenodo.2573969](https://doi.org/10.5281/zenodo.2573969)   [@ref-19]
  **discovery**       [EBI-GCA/reseqtrack/](https://github.com/EMBL-EBI-GCA/reseqtrack/tree/master/modules/ReseqTrack/Hive)\                                       [EBI-GCA/reseqtrack/](https://github.com/EMBL-EBI-GCA/reseqtrack/blob/master/docs/variantcalling_pipeline.txt)\                      [2.0](https://www.apache.org/licenses/LICENSE-2.0)                                                                                                                                     
                      [tree/master/modules/](https://github.com/EMBL-EBI-GCA/reseqtrack/tree/master/modules/ReseqTrack/Hive)\                                      [blob/master/docs/](https://github.com/EMBL-EBI-GCA/reseqtrack/blob/master/docs/variantcalling_pipeline.txt)\                                                                                                                                                                                                               
                      [ReseqTrack/Hive](https://github.com/EMBL-EBI-GCA/reseqtrack/tree/master/modules/ReseqTrack/Hive)                                            [variantcalling_pipeline.txt](https://github.com/EMBL-EBI-GCA/reseqtrack/blob/master/docs/variantcalling_pipeline.txt)                                                                                                                                                                                                      

  **Variant**\        [https://github.com/igsr/igsr\_](https://github.com/igsr/igsr_analysis/tree/v1.0.0/PyHive/PipeConfig/FILTER)\                                **BCFtools WGS variant**\                                                                                                            [Apache](https://www.apache.org/licenses/LICENSE-2.0)\   [http://doi.org/10.5281/](http://doi.org/10.5281/zenodo.2573911)\                                                             [@ref-18]
  **filtering**       [analysis/tree/v1.0.0/PyHive/](https://github.com/igsr/igsr_analysis/tree/v1.0.0/PyHive/PipeConfig/FILTER)\                                  **filtering pipeline:** [https://](https://igsr-analysis.readthedocs.io/en/latest/workflows/bcftools_wgs_filtering_pipeline.html)\   [2.0](https://www.apache.org/licenses/LICENSE-2.0)       [zenodo.2573911](http://doi.org/10.5281/zenodo.2573911)                                                                       
                      [PipeConfig/FILTER](https://github.com/igsr/igsr_analysis/tree/v1.0.0/PyHive/PipeConfig/FILTER)                                              [igsr-analysis.readthedocs.](https://igsr-analysis.readthedocs.io/en/latest/workflows/bcftools_wgs_filtering_pipeline.html)\                                                                                                                                                                                                
                                                                                                                                                                   [io/en/latest/workflows/](https://igsr-analysis.readthedocs.io/en/latest/workflows/bcftools_wgs_filtering_pipeline.html)\                                                                                                                                                                                                   
                                                                                                                                                                   [bcftools_wgs_filtering\_](https://igsr-analysis.readthedocs.io/en/latest/workflows/bcftools_wgs_filtering_pipeline.html)\                                                                                                                                                                                                  
                                                                                                                                                                   [pipeline.html](https://igsr-analysis.readthedocs.io/en/latest/workflows/bcftools_wgs_filtering_pipeline.html)\                                                                                                                                                                                                             
                                                                                                                                                                   \                                                                                                                                                                                                                                                                                                                           
                                                                                                                                                                   **BCFtools WES variant**\                                                                                                                                                                                                                                                                                                   
                                                                                                                                                                   **filtering pipeline:** [https://](https://igsr-analysis.readthedocs.io/en/latest/workflows/bcftools_wes_filtering_pipeline.html)\                                                                                                                                                                                          
                                                                                                                                                                   [igsr-analysis.readthedocs.](https://igsr-analysis.readthedocs.io/en/latest/workflows/bcftools_wes_filtering_pipeline.html)\                                                                                                                                                                                                
                                                                                                                                                                   [io/en/latest/workflows/](https://igsr-analysis.readthedocs.io/en/latest/workflows/bcftools_wes_filtering_pipeline.html)\                                                                                                                                                                                                   
                                                                                                                                                                   [bcftools_wes_filtering\_](https://igsr-analysis.readthedocs.io/en/latest/workflows/bcftools_wes_filtering_pipeline.html)\                                                                                                                                                                                                  
                                                                                                                                                                   [pipeline.html](https://igsr-analysis.readthedocs.io/en/latest/workflows/bcftools_wes_filtering_pipeline.html)\                                                                                                                                                                                                             
                                                                                                                                                                   \                                                                                                                                                                                                                                                                                                                           
                                                                                                                                                                   **Freebayes variant**\                                                                                                                                                                                                                                                                                                      
                                                                                                                                                                   **filtering pipeline:** [https://](https://igsr-analysis.readthedocs.io/en/latest/workflows/freebayes_filtering_pipeline.html)\                                                                                                                                                                                             
                                                                                                                                                                   [igsr-analysis.readthedocs.](https://igsr-analysis.readthedocs.io/en/latest/workflows/freebayes_filtering_pipeline.html)\                                                                                                                                                                                                   
                                                                                                                                                                   [io/en/latest/workflows/](https://igsr-analysis.readthedocs.io/en/latest/workflows/freebayes_filtering_pipeline.html)\                                                                                                                                                                                                      
                                                                                                                                                                   [freebayes_filtering\_](https://igsr-analysis.readthedocs.io/en/latest/workflows/freebayes_filtering_pipeline.html)\                                                                                                                                                                                                        
                                                                                                                                                                   [pipeline.html](https://igsr-analysis.readthedocs.io/en/latest/workflows/freebayes_filtering_pipeline.html)\                                                                                                                                                                                                                
                                                                                                                                                                   \                                                                                                                                                                                                                                                                                                                           
                                                                                                                                                                   **GATK variant filtering**\                                                                                                                                                                                                                                                                                                 
                                                                                                                                                                   **pipeline:** [https://igsr-](https://igsr-analysis.readthedocs.io/en/latest/workflows/gatk_vc_filtering_pipeline.html)\                                                                                                                                                                                                    
                                                                                                                                                                   [analysis.readthedocs.](https://igsr-analysis.readthedocs.io/en/latest/workflows/gatk_vc_filtering_pipeline.html)\                                                                                                                                                                                                          
                                                                                                                                                                   [io/en/latest/workflows/](https://igsr-analysis.readthedocs.io/en/latest/workflows/gatk_vc_filtering_pipeline.html)\                                                                                                                                                                                                        
                                                                                                                                                                   [gatk_vc_filtering_pipeline.](https://igsr-analysis.readthedocs.io/en/latest/workflows/gatk_vc_filtering_pipeline.html)\                                                                                                                                                                                                    
                                                                                                                                                                   [html](https://igsr-analysis.readthedocs.io/en/latest/workflows/gatk_vc_filtering_pipeline.html)                                                                                                                                                                                                                            

  **Variant**\        [https://github.com/igsr/igsr\_](https://github.com/igsr/igsr_analysis/blob/v1.0.0/PyHive/PipeConfig/INTEGRATION/VCFIntegrationGATKUG.pm)\   [https://igsr-analysis.](https://igsr-analysis.readthedocs.io/en/latest/workflows/consensus_callset_pipeline.html)\                  [Apache](https://www.apache.org/licenses/LICENSE-2.0)\   [http://doi.org/10.5281/](http://doi.org/10.5281/zenodo.2573911) [zenodo.2573911](http://doi.org/10.5281/zenodo.2573911)      [@ref-18]
  **integration**     [analysis/blob/v1.0.0/PyHive/](https://github.com/igsr/igsr_analysis/blob/v1.0.0/PyHive/PipeConfig/INTEGRATION/VCFIntegrationGATKUG.pm)\     [readthedocs.io/en/latest/](https://igsr-analysis.readthedocs.io/en/latest/workflows/consensus_callset_pipeline.html)\               [2.0](https://www.apache.org/licenses/LICENSE-2.0)                                                                                                                                     
                      [PipeConfig/INTEGRATION/](https://github.com/igsr/igsr_analysis/blob/v1.0.0/PyHive/PipeConfig/INTEGRATION/VCFIntegrationGATKUG.pm)\          [workflows/consensus\_](https://igsr-analysis.readthedocs.io/en/latest/workflows/consensus_callset_pipeline.html)\                                                                                                                                                                                                          
                      [VCFIntegrationGATKUG.pm](https://github.com/igsr/igsr_analysis/blob/v1.0.0/PyHive/PipeConfig/INTEGRATION/VCFIntegrationGATKUG.pm)           [callset_pipeline.html](https://igsr-analysis.readthedocs.io/en/latest/workflows/consensus_callset_pipeline.html)                                                                                                                                                                                                           

  **Phasing**         [https://github.com/igsr/igsr\_](https://github.com/igsr/igsr_analysis/blob/v1.0.0/PyHive/PipeConfig/INTEGRATION/PHASING.pm)\                [https://igsr-analysis.](https://igsr-analysis.readthedocs.io/en/latest/workflows/phasing_pipeline.html)\                            [Apache](https://www.apache.org/licenses/LICENSE-2.0)\   [http://doi.org/10.5281/](http://doi.org/10.5281/zenodo.2573911)\                                                             [@ref-18]
                      [analysis/blob/v1.0.0/PyHive/](https://github.com/igsr/igsr_analysis/blob/v1.0.0/PyHive/PipeConfig/INTEGRATION/PHASING.pm)\                  [readthedocs.io/en/latest/](https://igsr-analysis.readthedocs.io/en/latest/workflows/phasing_pipeline.html)\                         [2.0](https://www.apache.org/licenses/LICENSE-2.0)       [zenodo.2573911](http://doi.org/10.5281/zenodo.2573911)                                                                       
                      [PipeConfig/INTEGRATION/](https://github.com/igsr/igsr_analysis/blob/v1.0.0/PyHive/PipeConfig/INTEGRATION/PHASING.pm)\                       [workflows/phasing\_](https://igsr-analysis.readthedocs.io/en/latest/workflows/phasing_pipeline.html)\                                                                                                                                                                                                                      
                      [PHASING.pm](https://github.com/igsr/igsr_analysis/blob/v1.0.0/PyHive/PipeConfig/INTEGRATION/PHASING.pm)                                     [pipeline.html](https://igsr-analysis.readthedocs.io/en/latest/workflows/phasing_pipeline.html)                                                                                                                                                                                                                             

  **Benchmarking**\   [https://github.com/igsr/igsr\_](https://github.com/igsr/igsr_analysis/blob/v1.0.0/scripts/VCF/QC/compare_with_giab.nf)\                     [https://igsr-analysis.](https://igsr-analysis.readthedocs.io/en/latest/workflows/compare_with_giab_pipeline.html)\                  [Apache](https://www.apache.org/licenses/LICENSE-2.0)\   [http://doi.org/10.5281/](http://doi.org/10.5281/zenodo.2573911)\                                                             [@ref-18]
  **using Genome**\   [analysis/blob/v1.0.0/scripts/](https://github.com/igsr/igsr_analysis/blob/v1.0.0/scripts/VCF/QC/compare_with_giab.nf)\                      [readthedocs.io/en/latest/](https://igsr-analysis.readthedocs.io/en/latest/workflows/compare_with_giab_pipeline.html)\               [2.0](https://www.apache.org/licenses/LICENSE-2.0)       [zenodo.2573911](http://doi.org/10.5281/zenodo.2573911)                                                                       
  **in a Bottle**     [VCF/QC/compare_with_giab.](https://github.com/igsr/igsr_analysis/blob/v1.0.0/scripts/VCF/QC/compare_with_giab.nf)\                          [workflows/compare_with\_](https://igsr-analysis.readthedocs.io/en/latest/workflows/compare_with_giab_pipeline.html)\                                                                                                                                                                                                       
                      [nf](https://github.com/igsr/igsr_analysis/blob/v1.0.0/scripts/VCF/QC/compare_with_giab.nf)                                                  [giab_pipeline.html](https://igsr-analysis.readthedocs.io/en/latest/workflows/compare_with_giab_pipeline.html)                                                                                                                                                                                                              
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
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Version 1

**Summary**

The authors present a new call set from the 1000 genomes project. This time the call set is a fresh recall of the data against GRCh38. The call set is only composed of biallelic SNPs (biallelic in this study). Previous variant call sets on GRCh38 had been lifted over from their GRCh37 native counterparts. The study identifies SNPs by first calling variants with several algorithms, creating an union set and then explicitly genotyping these sites across the complete data set. The genotypes are then phased. A comparison with GIAB data for NA12878 is performed to assess the sensitivity and specificity of the call set.

**General observations**

A native call set of the 1000 genomes project data on GRCh38 is quite an important effort. These data have many important downstream uses including clinical genomics uses for variant filtering and population genomics studies. Notwithstanding the importance of this data set, I have issues with the data note as it stands. I think the paper simply described what the authors did to generate these data but makes little effort to explain why it was done in this way. The latter is important to gain confidence in the call set.

As a user of the data I would look to be satisfied with the quality of the call set. This is particularly important as several other large scale projects have released allele frequencies of many thousands of deep sequenced whole genomes (e.g. Topmed and Gnomad). In parallel, frameworks for assessing the analytical performance of variant calls have been proposed by GIAB and GA4GH and recently published. Truth sets for several important samples beyond the NA12878 have been released; including the ability to assess to how well phased the data sets was. As explained in the specific comments below, I believe more work should have been done to convince the reader that sufficient due diligence has been committed to this data set.

From the perspective of having a native call set on GRCh38 it is a shame that there is very little to show the potential benefits of this call set on GRCh38. There is no mention \[or I really missed it\] about how alternative haplotypes were handled and the implications of having variants in alternative haplotypes. The data release also ignores any non diploid areas of the genome.

From a methodological perspective, the tool chain feels outdated with BCFtools and GATK being at least 2 years old. Thresholds are widely used but little work is done to explain how these thresholds are determined. I assume that the parameters used in the tools themselves, these are standard or perhaps defined in previous iterations of the project. However, the filtering thresholds in Tables 1-4, at least from the reading, sounds like they were plucked out of thin air.

On a more positive note, I would like to commend authors for the great effort placed to make available the code, organising it, document it, and making this data set reproducible.

**Specific observations** \*Tool chain is really outdated\*. Is this because there have been little changes for the specific algorithms used (mpileup and unified genotyper?). I assume that many improvements and bugfixes have appeared in the last two years plus since these versions were released.\*Demonstrating improvements on GRCh38 and why it is better than the lift over\*. I missed some figure showing how this was an improvement. For example a comparison of the lifted over and the native call set. Are there regions of the genome where they perform different? Was it worth the effort? What about the ALTs, have we now better allele frequencies on these regions? How do they affect the frequencies on the corresponding frequencies on the primary assembly?\*Variant normalisation\*. This is glossed over in the text and little is said about how it was performed. In my experience this step often introduces difficult tradeoffs. Please expand on this.\*Benchmarking\*. This area is quite lacking here. I understand that you are only looking at biallelic sites so comparison with a truth set is easier. However, standards to doing this have existed for over a year and recently published. They are based on comparing at the haplotype level and not the site level.\*Phasing\*. These standards also enable comparing the phasing accuracy. Given the effort placed here to phase the genotypes, it would be helpful to also benchmark the phasing data.\*Union set\*. I would have loved to see a figure that shows how the various variant callers contributed to the union call set. Is there one that is unnecessary? Is there one that is responsible for many of the false positives?\*Analytical performance\*. \"Taken together, these results demonsrate both the high sensitivity and high specificity of our callset\". You seem to have less TP and more FN than in the 37 release. Now a days these numbers do not represent high sensitivity and specificity (at least with 30X genomes). At least a more nuanced discussion is required here. This is strongly linked to the thresholds you chose for various filtering steps.\*Truth sets\*. It would be very helpful to add further truth sets, for example for the Ashkenazim and Chinese trios.\*Joint calling\*. The approach here was to do single sample calling, assembling a union set and then genotyping those sites. Could the authors please explain why this approach as opposed to joint calling. I would assume that for low coverage genomes, joint calling may be more powerful as it can leverage information across more samples.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to state that I do not consider it to be of an acceptable scientific standard, for reasons outlined above.

Lowy

Ernesto

**Competing interests:**No competing interests were disclosed.
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First, we would like to thank the reviewer for the feedback that has been provided and for giving this work their attention.

In the general observations the reviewer notes that the data note is limited to a description of what was done, without significant discussion of the rationale behind the approach. We note that this is a data note, intended to describe a data set and how it was produced, however, we have also amended the text to include more detail relating to the rationale behind our approach.

Also, in general observations, the reviewer highlights issues relating to data quality: other call sets, the limitation of comparing to only NA12878 and benchmarking phasing. While other call sets, such as TOPmed and gNOMAD exist, the 1000 Genomes Project data set remains unique in terms of its composition of populations and that all data can be accessed to the base pair level. With regard to other truth sets, beyond NA12878, we were unable to locate "gold-standard" data for any other samples in our data set. With regard to phasing, we have used the WhatsHap program to assess this and added the results to the manuscript.

With regard to GRCh38, our aim was not to demonstrate the superiority of GRCh38 but rather to provide a resource for those wishing to use that assembly. We believe the benefits of the assembly have been demonstrated by Schneider *et al*.

We have amended the text to make it clearer that calling was not done on alternate loci. The text has also been amended to describe the intention of using the data note format to release and describe data early, with the intention being to revisit elements not included in this set.

With regard to the tool chain, this reflects the volume of compute involved in this work. It was around two years ago that this work commenced. The final stage of the pipeline alone takes around six months to run, even with access to generous compute resources.

The text has been amended to include information on threshold selection.

With regard to the detailed points:

**1) Tool chain is really outdated**

Software versions reflect the length of time required to run this compute, as noted above. 

**2) Demonstrating improvements on GRCh38 and why it is better than the lift over**

As noted above, our intention was not to demonstrate that GRCh38 was the better assembly. We consider that this has been done previously by Schneider *et al*. We have added a comparison with the liftover.

**3) Variant normalisation**

We have updated the text to include further information on this.

**4) Benchmarking**

We note that hap.py was published after this work was submitted. We were unable, however, to establish from the manuscript how it could be used to improve upon the existing benchmarking. The summary provided in Figure 1 (https://www.nature.com/articles/s41587-019-0054-x) indicates that it wraps tools for arriving at consistent representation of variants (handled in the normalisation steps of our pipeline at the point of producing the consensus call set) and then produces a "standardised" report, providing similar metrics to those we present. From this, it appears to provide similar functionality to steps already present in our work. Our attempt to contact the authors for more information on this was not successful.

With regard to our decision to use a "truth set", our belief is that comparing to an independently produced "gold-standard" is a valuable benchmarking strategy.

We have extended the benchmarking using WhatsHap.

**5) Phasing**

This has been done with WhatsHap and the results added. As noted above, our attempt to contact the author of hap.py to establish how it could be used to benchmark phasing was sadly unsuccessful.

**6) Union set**

We have added the requested figure.

**7) Analytical performance**

These statements were made in the context of comparison with the phase three call set. The text has been amended. We have also compared with an initial analysis of new 30x coverage data produced by standard pipelines at NYGC. Based on our benchmark, the performance of our call set is slightly better. We agree that filtering has an impact here.

**8) Truth sets**

Our calling approach used low-coverage and exome data from the period of approximately 2008 to 2012 to perform joint genotyping. We believe that there would be questions about the validity of trying to benchmarking our results with samples that are simultaneously (1) not part of one of our populations, (2) have different relatedness to other samples in the population, and (3) have different data types available for variant calling. This excludes the Ashkenazi samples as a suitable benchmark. For the Han Chinese samples, we could not locate data that matches the profile of that for our samples. We have updated the text in an effort to improve the discussion of issues relating to benchmarking.

**9) Joint calling**

This did use joint calling. The text has been amended to make this clearer.
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Version 1

**Summary**

In the work entitled \'Variant calling on the GRCh38 assembly with the data from phase three of the 1000 Genomes Project\', Lowy-Gallego *et al.* describe their effort to re-analyze the 1000 genomes data on the current GRCh38 assembly. They do not perform a full variant analysis, but rather release a set of biallelic SNVs as a preliminary variant call set. They compare this variant set to the Genome in a Bottle (GIAB) variant calls on the sample NA12878.

**High Level Comments**

It is great to see efforts to update important datasets onto the current human reference assembly, GRCh38. As the authors note, the GRCh38 reference represents a substantial improvement over the GRCh37 reference, but the lack of GRCh38 based annotation has hindered adoption of this version of the reference assembly. The authors go on to discuss why \'lift-over\' based approaches are inadequate, which motivated this work. I agree that \'lift-over\' based approaches are inadequate, but I find the results presented in this manuscript unconvincing with respect to this assertion.

The authors spend significant space in the introduction on both explaining the improvements in GRCh38, including the addition of alternate loci, but then put no effort into demonstrating why these are valuable. Additionally, the authors spend time discussing why \'lift-over\' based approaches are inadequate, but then do no comparisons to show why their *de novo* approach is an improvement.

While I believe this work is important, I feel the authors fail to make the point of why doing this *de novo* analysis on the GRCh38 reference is important.

**Detailed Comments**

1\. **Explanation of why \'lift-over\' approaches have limitations:**I agree with the statement that \'lift-over\' is inadequate. However, the description of this on page 1 is not clear. Statement 1 \'they rely on an equivalent region existing in the new genome, so new sequence in the improved assembly is effectively excluded\' confounds two points. Regions that are present on the old assembly but no the new one will be excluded from a \'lift-over\' approach. Additionally, sequence that is new on the updated reference will also be omitted - but these are two separate cases.

Point 2, relating two alignments also confounds multiple issues. Yes - correct alignments are key to the \'lift-over\' approach, but there are two \'bad alignment\' cases. The case I **think** the manuscript is referring to is a case where increased diversity in one version of the assembly can confound alignments (that is, sequence change). The other relevant case is the addition of paralogous sequence to one assembly that is missing from the other. This can lead to a locus aligning to a paralogous region rather then the equivalent locus (I have seen examples of this), that can also lead to incorrect \'lift-over\'. Point three in this statement is a clear statement, but the authors provide no evidence to actually support this.

2\. **The authors only provide biallelic SNPs:** I can see the utility in concentrating on a restricted set of variants, but only if this set of data are actually used to demonstrate the value of *de novo* analysis over \'lift-over\', which was not done in this manuscript. On page 3, the authors state that \"These represent the major part of the SNVs present in the human genome.\" but I\'d like more hard numbers on this. What percentage of all SNVs do the biallelics represent? What percentage of all variation do they represent?

3\. **Page 3, Quality control of alignment files:** Are the steps presented here just the differences from the original protocol? I think this is OK, but it is not clear from reading the manuscript if this is the full set of steps or just the differences.

4\. **Variant discovery:** Why did you use the variant calling tools you chose?

5\. **Variant Filtering:** The omission of variants from the sex chromosomes seems like a significant omission and limits the use of this dataset.

6\. **Data set validation:** I have significant concerns here. I understand why NA12878 was used for some validation. However, my understanding is that the GIAB dataset does not take the alternate loci into account in their variant calling, while this manuscript tries to take advantage of these sequences - how did this impact the comparison? For example, I would predict more conflicts in regions where alt-loci exist in GRCh38. Does this occur?

I am also not convinced that accuracy on NA12878 really translates well to other samples, particularly non-European samples (as NA12878 has a European ancestry). Will the accuracy really extend to non-European samples? Also, my reading of Table 5 is that this dataset performs slightly worse than the GRCh37 call set. This does not do a lot to convince this reader that the work of doing the re-analysis is worthwhile - and I\'m a believer, based on previous work I have been a part of! I have some concerns that this may be due to improvements in the new call set (due to the inclusion of the alts and more complex decoy) but it takes some significant work to track this down. There are examples of this kind of analysis ^[@rep-ref-35051-1]^. The authors should also clearly state what fraction of the genome they are able to assess using this method.

7\. **Omitted analysis:** The authors discuss the value of the improved reference in the introduction, but then do nothing to show the value of the alternate loci. How many new variants are identified on these loci? How does the inclusion of these sequences change variant calling on the primary?

Perhaps most disappointing is that there is no analysis of how the *de novo* is an improvement over \'lift-over\' approaches. How do the *de novo* variant calls compare to the \'lift-over\' calls? Without this analysis, it is unclear to me that anyone would be convinced that doing the *de novo* call approach is worth the effort.

Lastly, the authors miss the opportunity to do an accuracy comparison by looking at the regions of the reference comprised of the \'ABC\' clones. These are fosmid libraries constructed from several of the samples that went into the 1000 genomes project. These provide a great test bed for both looking at variant calls (any call in this region should be heterozygous or hemizygous as the reference sequence represents one valid haplotype in the sample being analyzed) and also allows for the confirmation of the local haplotype assertions.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to state that I do not consider it to be of an acceptable scientific standard, for reasons outlined above.

Lowy

Ernesto

**Competing interests:**No competing interests were disclosed.
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First, we would like to thank the reviewer for the feedback that has been provided and for giving this work their attention.

We note the high level comments are broken down into detailed points and addressed with detailed comments below. We have further updated the manuscript in an effort to improve clarity where it was indicated this was lacking. We also provided the requested information comparing the generated call set with the lift-over and included assorted other updates.

In response to the high level comments, which we understand to primarily relate to a) the improvements of GRCh38 over GRCh37 and b) comparison between *de novo* calling versus lift-over:

a\) It was not our intention to demonstrate the superiority of GRCh38 over GRCh37. We believe that the GRC, in particular in the paper by Schneider *et al.*, have demonstrated this already. We included information on this for the information of readers who may not be familiar with these issues. However, we accept that this may give an inaccurate impression of the emphasis of the data note. As such, the text has been amended, reducing the explanation of assembly changes and, rather, making reference to the paper by Schnieder *et al*. Our aim was to provide a resource for those wishing to adopt the new assembly, not to present the case as to why GRCh38 should be adopted, which we believe has already been made elsewhere.

b\) Our emphasis is on providing resources for the community. To make the data available to users in as timely a manner as possible, we elected to use the data note format for publication. This has a focus on describing how the data was produced, with validation of data outputs being listed in the information to authors as optional. In light of the comments, we have performed a comparison with the lift over set and also looked specifically at regions of the assembly that were updated between the two assemblies. Further details are below.

**1) Explanation of why "lift-over" approaches have limitations:**

This relates to a set of three statements regarding the inadequacy of lift-overs.

For the first statement, the reviewer notes that the removal of sequence when moving from GRCh37 to GRCh38 and the gain of sequence are two separate cases and that these were conflated in the statement "they rely on an equivalent region existing in the new genome, so new sequence in the improved assembly is effectively excluded". We accept that this combines multiple facets of changes between the two assemblies. The text for statement one has, therefore, been updated to focus on the central point that we sought to make: that a mapping between the assemblies is necessary before one can lift-over a given variant and that this is not always possible (for any one of a number of possible reasons). Further, we have added the number of records that could not be lifted over in the dbSNP/EVA processed files to give a concrete indication of the numbers of records where this occurs.

For the second statement, the point we wished to make was that, even when a variant can be lifted-over, it does not follow that the evidence that supported that call in the original assembly would also transfer to the new location. The text has been amended in an effort to make this clearer, also citing evidence from Schneider *et al.* in regard to alignments and the transition from GRCh37 to GRCh38.

For the third statement, it was noted that this was clear but that no evidence was provided to support the assertion. In light of the other changes, this text has been modified to focus on the case of new sequence being added to the assembly and pointing to specific examples shown as part of Figure 1, which illustrate the differences in the lift-over and *de novo* call sets at examples of clinically relevant loci, which were updated between the two assemblies

**2) The authors provide only biallelic SNPs:**

The requested comparison with the lift-over is addressed in the response to point seven. We have added the requested numbers relating to what fraction of SNVs are biallelic (99.6%) and the number of SNVs relative to other short variants. We have also taken the opportunity to update the call set to include biallelic INDELs, a category of variant that was not previously included. Multi-allelic calls remain absent from the set as SHAPEIT is unable to handle such calls and our pipelines would require further development. Our strategy has been to release calls as soon as possible and to revisit the data set adding additional classes of variant as practical. This was done with the aim of making data useful to many available and with the intention of revisiting the data set to extend it as useful.

**3) Page 3, Quality control of alignment files:**

All of the steps used are described in the data note, not just the differences. The text has been updated in an effort to make this clearer to readers.

**4) Variant discovery:**

Tools were chosen in consultation with members of the 1000 Genomes Project Consortium. While our aim was to recapitulate their GRCh37 analysis on the new assembly, this would not have been feasible given the large number of callers used in the original project, the concomitant compute and the relatively complex methods used in filtering and integrating call sets, which were both compute and labour intensive. This obliged us to look at using a reduced set of callers and a simplified methodology. We sought recommendations that took into account the performance of the callers on the 1000 Genomes phase three data, which unlike most other panels is a mix of low coverage and exome with significantly more geographic diversity. In addition, the performance of some callers on the data set rendered their use impractical.

The text has been updated to inform readers of the above.

**5) Variant filtering:**

This was intended to be an initial release of data, with the intention of revisiting and adding additional elements that require further processing. As the sex chromosomes required additional analysis, they were not included in this first release. Further, we believe that the data set is still beneficial to some users in their absence. We anticipate calls on the GRCh38 sex chromosomes being released in the future.

**6) Data set validation:**

We acknowledge that the GIAB NA12878 benchmark is imperfect. As the reviewer notes, it is a single sample and the differences in the versions of the reference genome used for alignment (with and without alternate loci) by us and GIAB would be expected to have a bearing on variant detection.

With regard to the alternate loci, the possibility of comparing the level of conflict with the benchmark at regions where alternate loci are present and where they are not is mentioned. Given, however, that the presence of the alternate loci would also be expected to have at least some impact across the genome (irrespective of the presence of alternate loci at that particular location), we feel that, in order to truly assess what impact the alternate loci had on the analysis, it would be necessary to repeat the analysis, using, instead, alignments where the alternate loci had not been present. As our data set also relies on joint genotyping, this would effectively mean realigning all of the data and repeating analysis on all of the data in order to answer this question. The substantial compute volume involved in this would add significant time and expense and, thus, makes this comparison impractical. It would, however, be necessary in order to derive meaningful and sound conclusions about the impact of the alternate loci on our analysis.

The reviewer also expresses concern that accuracy with NA12878 may not transfer to other samples, particularly those of non-European ancestry. Given the prevalence of data from NA12878, it would seem reasonable to conclude that calling methods should perform well, and potentially above average, with that sample. However, NA12878 has data similar to that of other samples in our data set. Further, our data set is comprised only of Illumina data, so we do not expect, for example, types of sequencing error to vary across the samples. In work done by others, comparing the new call set to 1000 Genomes phase three, we see that our results and those for phase three show a strong level of consistency across the samples (Robinson and Glusman, 2019, https://www.biorxiv.org/content/10.1101/600254v1), with no indication that NA12878 is an outlier.

In relation to our comparison with phase three, it was not our intention to try to outperform phase three, rather to offer a *de novo* call set of similar quality on GRCh38. The utility is to those wishing to work with GRCh38 and work with a *de novo* call set generated on that assembly including the novel GRCh38 regions. The comparison with phase three is offered to assist users in understanding how our call set compares to phase three. Our call set shows broadly similar behaviour to phase three, with a slightly different balance of sensitivity and specificity. Given, however, that phase three involved a massively greater analysis effort, which resources would make impossible to repeat, it is perhaps not surprising that phase three sees a higher yield. In turn, this is reflected in the lift-over but with substantial differences demonstrated in novel regions where the *de novo* call set detects variants absent in the lift-over.

While we do acknowledge the limitations of the GIAB benchmark we have used, we found no better alternatives. To effectively benchmark our data, based as it is on joint genotyping, we needed "gold standard" data for samples in our data set. For short variants, the only such data set we were able to locate was GIAB NA12878. The alternatives, of manual inspection of the data or alternative data types, such as PacBio reads being assessed by us also have limitations and lose the benefits gained from an independent "gold standard" data set created by another group.

The text has been updated in an effort to better reflect the above.

**7) Omitted analysis:**

The alternate loci were used in aligning reads to ensure the best possible read mapping but variants were not called on these loci. The text has been amended to make this clearer. This is in large part as protocols for successfully calling on the alternate loci are lacking. The only information provided by developers of calling software of which we are aware in relation to this is a beta tutorial from GATK (https://software.broadinstitute.org/gatk/documentation/article.php?id=8017). Due to the lack of tools and protocols for confidently calling on the alternate loci, calls were not made at those loci.

We have extended our benchmarking work to include the lift-over data set in the comparison. We have also looked specifically at novel regions of GRCh38. These are included in the revised text.

The suggestion relating to fosmid clones is interesting and would provide further validation. We would, however, note that this is a data note, offered by the journal as a means of describing the production of a data set, where benchmarking is described as optional. Our existing benchmarking covers the genome at greater scale and should, therefore, already give a better indication of the performance of our calling genome wide. Further, we have added benchmarking of the phasing using WhatsHap.

[^1]: No competing interests were disclosed.
